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ABSTRACT 
The multifactorial nature of Alzheimer' s Disease suggests that complex gene-gene 
interactions are present in AD pathways. Contemporary approaches to detect such 
interactions in genome-wide data are mathematically and computationally challenging. 
We investigated gene-gene interactions for AD using a novel algorithm based on co-
operative game theory in 15 genome-wide association study (GWAS) datasets 
comprising of a total of 11,840 AD cases and 10,931 cognitively normal elderly controls 
from the Alzheimer Disease Genetics Consortium (ADGC). We adapted this approach, 
which was developed originally for solving multi-dimensional problems in economics 
and social sciences, to compute a Shapely value statistic to identify genetic markers that 
contribute most to coalitions of SNPs in predicting AD risk. Treating each GW AS dataset 
as independent discovery, markers were ranked according to their contribution to 
coalitions formed with other markers. Using a backward elimination strategy, markers 
with low Shapley values were eliminated and the statistic was recalculated iteratively. 
We tested all two-way interactions between top Shapley markers in regression models 
Vl 
which included the two SNPs (main effects) and a term for their interaction. Models 
yielding a p-value<0.05 for the interaction term were evaluated in each of the other 
datasets and the results from all datasets were combined by meta-analysis. Statistically 
significant interactions were observed with multiple marker combinations in the APOE 
regions. My analyses also revealed statistically strong interactions between markers in 6 
regions; CTNNA3-ATP11A (p=4.1E-07), CSMDl-PRKCQ (p=3.5E-08), DCC-UNC5CL 
( p=5.9e-8), CNTNAP2-RFC3 ( p=1.16e-07), AACS-TSHZ3 (p=2.64e-07) and CAMK4-
MMD ( p=3.3e-07). The Shapley value algorithm outperformed Chi-Square and ReliefF 
in detecting known interactions between APOE and GAB2 in a previously published 
G WAS dataset. It was also more accurate than competing filtering methods in identifying 
simulated epistastic SNPs that are additive in nature, but its accuracy was low in 
identifying non-linear interactions. The game theory algorithm revealed strong 
interactions between markers in novel genes with weak main effects, which would have 
been overlooked if only markers with strong marginal association with AD were tested. 
This method will be a valuable tool for identifying gene-gene interactions for complex 
diseases and other traits. 
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Chapter 1: Introduction 
1.1 Overview of the Dissertation 
The goal of the dissertation is to find gene-gene interactions that might explain some of 
the unexplained heritability in Alzheimer's Disease (AD). I introduce a method based on 
co-operative game theory that has the ability to quickly parse through millions of Single 
Nucleotide Polymorphisms (SNPs) from Genome-Wide Association Studies (GWAS) 
and assign a relevance-index to every candidate SNP. Based on the relevance scores, I 
prioritize SNPs to be tested for two-way interactions that might confer risk to 
Alzheimer's Disease. I test the 2-way interactions of the top SNPs for association with 
AD in several AD GW AS datasets and summarized my findings. 
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Chapter 1 provides a detailed overview of epistasis in complex diseases, methods used to 
find epistasis in GWAS and the challenges associated with it. Sections 2 and 3 describe 
the strategies and methods used for testing epistasis in complex diseases and the strengths 
and weaknesses of these approaches. Section 4 describes the genetics of AD and the 
latest findings in the field . It makes a case of testing epistasis as an attempt to understand 
the large unexplained heritability in AD. Section 5 gives a basic introduction of co-
operative game theory and lays the foundation for application of the algorithm to genetic 
data. 
Chapter 2 explains the nuts and bolts of the Shapley Value algorithm and its application 
to genetic data. Section 1 and 2 introduce the concept of co-operative games and the 
Shapley solution to determine the worth (or contributions) of players in a coalition. 
Section 3 goes over definitions and notations that aid in explaining the theory behind the 
game theoretical model applied to genetic data. Section 4 explains how the Shapley 
Value algorithm is used to assign relevance to players in the context of genetic data. 
Chapter 3 describes the cohorts that participate in the Alzheimer Disease Genetics 
Consortium (ADGC). Section 2 explains the quality control protocol used to ensure 
consistency and veracity of GWAS data and reduce background noise by excluding low 
quality SNPs and subjects from analysis. 
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Chapter 4 provides a detailed account of the analysis strategy using the Shapley Value 
algorithm to find interactions in the ADGC datasets. Sections 1 and 2 give the details of 
the analysis strategy employed to a) prioritize SNPs to be tested for interaction and b) 
testing interactions in a multi-GWAS dataset. Section 3 describes the burden of testing 
millions of interactions and multiple testing correction needed to establish significance. 
Section 4 lists the observations from running the Shapley Value algorithm on genotyped 
and imputed sets of SNPs in the ADGC datasets and summarizes the list of important 
findings . Section 4 also describes the results obtained by testing interactions amongst the 
highly ranked Shapley SNPs. 
Chapter 5 compares the Shapley Value approach to existing filtering algorithms that 
prioritize SNPs to be tested for interactions in genome-wide data. Section 1 compares 
prioritizing SNPs to be tested for interaction based on Shapley Value to P-value in the 
ADGC dataset. Section 2 compares the different approaches using simulated data. 
Section 3 discusses the strengths and weaknesses of the algorithm and how it can be used 
in conjunction with sophisticated techniques such Multifactor Dimensionality Reduction 
to determine the presence of higher order or non-linear interactions in AD. 
Chapter 6 summarizes and discusses the results obtained from all aspects of the project 
and outlines future directions that this project could possibly take. 
1.2 Epistasis in Complex Diseases 
3 
Epistasis or Gene x Gene interaction has been studied for over a century [1]. Epistasis is 
defined as the masking of effect of a Mendelian locus by another locus. In contrast, 
statistical geneticists define epistasis as the deviation of average phenotypic values of two-
locus genotypes from those expected by summing or multiplying the allelic effects due to 
additivity and dominance at the loci on a linear or multiplicative scale respectively. 
Gene x Gene Interactions have been investigated in various paradigms such as classical 
quantitative genetic studies of inbred plant [2-4] and animal populations [5], evolutionary 
genetic studies and more recently in human linkage and association studies. In this report, 
we will compare and contrast the approaches used to find interactions in genetic 
association studies in humans for complex diseases. 
Complex diseases can be sufficiently explained only by unraveling interactions among 
risk genes and the environment which can then be used to make therapeutic targets [6-8]. 
Epistasis can exist between genes with significant marginal effects on the disease or 
between genes that do not have an influence on the phenotype by themselves but interact 
to increase the risk of the disease. Epistasis between genes with significant marginal 
effects have been discovered in type-1 diabetes [9, 10], type-2 diabetes [11], breast [12], 
prostate [13] and colorectal cancer [14] . Interactions modulated in the presence of one 
significant marginal effect have been found in autism [15] and cervical cancer [16]. 
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Examples of interactions between genes in the absence of the any significant main effects 
have been observed in Alzheimer's disease [17] and type II diabetes [18]. 
1.3 Detecting epistasis in genetic data 
1.3.1 Introduction 
Genome-Wide Association Studies have enabled the identification of many disease-
related polymorphisms in the last five years. Interest is now focusing on finding effects 
explained by gene-gene or gene-environment interactions that might not be identified by 
using standard single-locus tests. Detecting such interaction effects between loci will 
allow us to understand in greater detail, the biological and biochemical pathways that 
underpin disease. 
1.3.2 Methods to detect epistasis in genetic association data 
Methods to detect epistasis depend on the study design for collecting genetic association 
data. Different approaches are used for case-control and family based studies. The 
methods can be roughly categorized into three major categories: 
a) Regression-based: Linear and logistic regression models have been traditionally used to 
test for interaction for quantitative and dichotomous traits respectively. Statistical 
interaction is tested on the log odds scale by fitting a logistic regression model [19] by 
forming products of variants representing individual effects. The model includes marginal 
and interaction effects of the variables and the null hypothesis the interaction term equals 
zero is tested. Almost any statistical package can be used to test such an interaction 
framework. Alternatively Plink [20] provides an --epistasis option to test interactions 
assuming an allelic model for the main effects and interactions. 
To cope with the large number of two-way and possibly higher order interaction tests in 
whole-genome data, two strategies are commonly used; step-wise and two-stage 
regression. Step-wise regression identifies the optimal number of candidate loci to be 
included in a regression model [21-23]. Examples of 'stepwise-like' regression include 
forward stepwise logistic regression[22] , LASS0[24] , and logic regression [25]. Logic 
regression was developed by Kooperberg et al [26] for the purpose of reducing the 
dimensionality caused by SNP combinations and tests logical combinations of SNPs that 
are associated with the outcome of interest. 
5 
Step-wise regression is usually carried out in two stages. The first stage selects a few 
important markers to be tested for interaction. The second stage tests for interactions 
involving the markers selected in the first stage. Two approaches have been used in a two-
stage analysis. Marchini et al[27] use a liberal cutoff (p<O.l) in the first stage to select a 
few thousand markers and test all the two-way interactions between those markers. Hoh et 
al [28] propose a more stringent cutoff in the first stage (p<l Oe-6) to select a handful of 
markers and test their interactions genome-wide. Ionita and Man [29] compared these two-
step methods and found that statistical power is improved slightly by conditioning on the 
initial marker loci. Another mutli-stage approach, called the Focused Interaction Testing 
Framework (FITF) [30] , performs likelihood-ratio tests in stages to allow for joint tests of 
main effects and interactions conditional on significant lower-order effects. The number of 
stages depends on the maximum order of interaction desired. 
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b) Data Reduction Methods: Traditional regression-based approaches are not efficient in 
dealing with high dimensional genome-wide data and nonlinear models that contain 
potentially many interacting predictor variables resulting in data sparsity. Hence data-
mining and reduction techniques are used as non-parametric methods to fit a theoretical 
model given the experimental data. They reduce the dimensionality of data by pooling the 
multi-locus genotypes into groups. Two such methods for data reduction are 
Combinatorial Partitioning Method (CPM) (used primarily for quantitative traits) and 
Multifactor Dimensionality Reduction (MDR) (developed using the CPM paradigm for 
dichotomous traits). The CPM [31] algorithm originally developed for quantitative traits 
clumps genotypes with similar phenotype values into partitions and selects the partitions 
that explain a certain level of variance in the data. Multi-fold cross validation is used to 
select a partition that has consistent predictive power uninfluenced by chance splitting of 
the data into training and testing sets. Inferences are then made based on the most 
predictive partitions. However the number of partitions increases exponentially with the 
number of loci considered. For example two SNPs which have nine two-loci genotypes 
(pairs drawn from {AA,Aa,aa} and {BB,Bb,bb}) can be partitioned into subsets of2, 3, 
... , 8 two-loci genotypes. Two subset partitioning of2-loci genotypes (such as {AABB, 
aabb} as one subset and the rest as the other) can be done in 255 ways. When the same 
steps are repeated for subsets of 3, 4, ... , 8, there are 21,146 ways of partitioning all the 
nine 2-locus genotypes. The complexity of computing all subsets of two-loci genotypes 
for every pair of SNPs renders the algorithm computationally intractable for even 
moderate number of loci. 
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The MDR method proposed by Ritchie et al [32] pools multi-locus genotypes into a single 
dimension with two groups- one classified as having high risk of the outcome and the 
other as low risk. The algorithm divides the data randomly in training and testing sets. It 
considers a few hundred markers called 'factors' to begin with and chooses n markers 
from the set. The multifactor cells are then represented inn-dimensional space. Each 
multifactor cell is labeled as 'high-risk' if the ratio of cases to controls exceeds some 
threshold, else 'low-risk'. This process reduces then -dimensional multifactor classes into 
a one dimensional model with two multifactor classes: high and low risk. These steps are 
repeated for all other n factor combinations and the n factor model which has the fewest 
misclassified individuals in the training set is chosen as the 'best' n factor model. Finally, 
the classification from the ' best' n factor model is used to predict disease status for the test 
data set. A ten-fold cross validation is applied to avoid bias due to chance divisions of the 
data. The MDR approach first considers all two-factor combinations and chooses the 
single best two-factor model with the lowest prediction error among all two-factor 
combination models. When computationally feasible, this process is then repeated among 
all possible higher order factor combinations, with a best model chosen at each step. The 
MDR method has been applied to detect gene x gene interactions in common human 
diseases such as autism [15] and type II diabetes [33] . 
c) Pattern Recognition Methods: Pattern recognition methods are used to overcome the 
limitations of data loss in the data reduction methods. These methods isolate genotypic 
patterns from the data that predict the phenotype. These genotype patterns are used to 
detect and characterize interactions among genes. Some of the recently used pattern 
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recognition methods are cellular automata approaches [34], neural networks [35] and 
genetic algorithms. Most of these methods with the exception of neural networks have not 
been used to detect epistasis in real datasets. 
1.3.3 Methodological Issues in detecting epistasis 
Factors complicating the modeling of epistasis can be summarized as a) data sparsity, b) 
computational complexity, c) multiple testing and d) overfitting. 
Data Sparsity: Limited sample sizes to unravel modest interactions and low minor allele 
frequencies can lead to data sparsity that results in problems like improper fit, non-
convergence of the statistical model and violation of the asymptotic properties of the test 
statistic. Regression models are not robust when sparse strata result in a singular design 
matrix. This problem can be overcome by ignoring categories with very few observations 
which in turn can lead to loss of power. Pooling of categories by testing dominant or 
recessive modes of inheritance reduces three distinct genotype classes to two categories 
alleviating the problem of sparse data. Statistical methods such as Fisher's exact test and 
generalized Cochran-Mantel-Haenszel test are designed to handle problems of data 
sparsity. 
Computational Complexity: Testing all possible two-way interactions results in a number 
of tests which is quadratic in the order of the number of single loci tested. Three way 
interactions increase the number of tests to a cubic order and the number of tests increases 
exponentially for higher-order interactions. For genome-wide data, the computational 
burden is so enormous that an exhaustive search for interactions is not computationally 
feasible. Sample sizes required to detect higher order interactions are often not available 
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and biological interpretation of high-dimensionality interactions is complex. Hence only 
possibly relevant interactions (hypothesized on evidence of biological function or prior 
genetic association) are tested and several strategies to prune the data to computationally 
manageable limits have been proposed. A priori biological knowledge and data driven 
approaches are used to restrict the search space and maximize the probability of detecting 
true interactions. 
Multiple Testing: Testing a large number of interactions results in multiple testing 
inference problems. The problem is exacerbated by a large number of tests and hidden 
correlations between the tests arising from testing common loci interactions and linkage 
disequilibrium between the markers tested. Conservative correction measures like the 
Bonferroni, a method that controls the family-wise error rate may result in missing true 
interactions. Alternatively, less conservative measures like the False Discovery Rate 
(FDR) [36], which is defined as the expected proportion of rejected null hypotheses that 
are falsely rejected, can be used for type 1 error. The q-value method [37], closely 
resembling the FDR approach, have also been used to correct for multiple testing. 
Failure to appropriately control errors due to multiple testing leads to reduced power in 
genome-wide association studies [38]. Small sample sizes of current GWAS studies 
compound the problem of detecting moderate effect sizes of risk variants and their 
interactions. Linear models have lower power to detect interactions than data-driven 
methods because variation associated with the interaction is subsumed into the variation 
explained by the main effects in the model [39]. 
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1.4 Genetics of Alzheimer's Disease 
1.4.1 Introduction 
Alzheimer's Disease (AD) is a progressive neurodegenerative disorder and the primary 
cause of dementia amongst people older than 65 and it has a strong genetic predisposition 
(60-80% population attributable risk) . It has an estimated prevalence of 10-30% by age 85 
or older and an incidence of 6-8% in the same age group [ 40] . AD is an epidemic with 
major health costs; there are 3-4 million affected individuals in the United States and 
around 350,000 new cases added per year and the average annual budget for caring for AD 
patients estimated to be around 10 billion dollars [ 41, 42]. In the absence of preventive 
measures to delay the onset of the disease, the prevalence is expected to cross 13 million 
in 2050 [ 42]. Brookmeyer et al [ 42] estimated that the 50-year projected prevalence of AD 
could decrease by 380,000 individuals, ifthere were an intervention to delay disease onset 
by a mere 6 months, corresponding to annual savings of nearly $18 billion after 50 years. 
AD is characterized by massive neuron loss in the brain. The onset of AD is signaled by 
atrophy in the medial temporal lobe and the hippocampus. It then results in massive 
synaptic degeneration and neuronal death. The major histological observation in an AD 
brain is in the intracellular accumulation of neurofibrillary tangles (NFT). 
Hyperphosphorylation of the 't protein is observed in the NFT leading to neuronal 
degeneration through deleterious effects on axonal transport mechanisms and cell shape. 
Another major pathohistological phenotype observed in the AD brain are the presence of 
extra-cellular senile plaques comprised of the ~-amyloid protein. The ~-amyloid plaques 
are characterized the presence of two peptides; A~40 and A~42 peptides produced by 
proteoloytic breakdown ofthe Amyloid Precursor Protein (APP) by BACE1/~ and the 
presenilin/A, secretases [ 4 3]. 
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AD is differentiated by early and late onset forms of the disease. The early onset form of 
the disease usually segregates in families and occurs before the age of 65 . It is usually 
caused by rare autosomal dominant mutations in genes encoding the APP and presenilin-1 
and 2 (PSENl and PSEN2) proteins. 
1.4.2 Review of findings in the genetics of AD 
AD is a complex multifactorial disease caused by several interacting genetic and 
environmental determinants. AD is characterized by presence of genetic heterogeneity and 
there is no single model explaining the genetic mode of inheritance of the disease. Over 
the last two decades, Apolipoprotein-E (APOE) has been the single robust genetic finding 
in AD [44, 45]. The £4 isoform of the APOE gene almost doubles the risk of disease 
compared to the longer and most commonly occurring £3 wild-type, whereas the £2 
isoform has a protective effect. According to current estimates APOE contributes about 
20% to AD attributable risk [46]. Post APOE, several candidate-gene studies found over 
660 genes [ 4 7] that might contribute to AD risk; however none of these regions were 
replicated consistently across multiple studies. Most candidate studies were underpowered 
and faced other methodological issues [ 4 7] . 
With the advent of Genome-Wide Association Studies (GW AS), studies in AD were 
powered with large sample sizes containing thousands of cases and controls. Between 
2007 and 2009 several G WAS with low sample sizes of 1000 cases and controls revealed 
some interesting candidate genes that might confer AD risk [48-52]. In 2009, two large 
AD consortia- the European AD Initiative (EADI) [53] and the Genetic and 
Environmental Risk in AD (GERAD) [54] published back to back studies spanning 
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several thousand AD cases and controls. They found evidence of genome-wide association 
for three new genes; the complement receptor- I (CRI), Clusterin (CLU) and 
phosphatidylinositol-binding clathrin assembly protein (PICALM). The Cohort for Heart 
and Aging Research in Genomic Epidemiology (CHARGE) [55] conducted a meta-
analysis using their datasets along with the data in the EADI and GERAD consortia 
uncovering the Bridging Integrator- I (BINI) gene as another Alzheimer Susceptibility 
locus. Even though the estimates are biased upwards (since they are not based on 
longitudinal studies), the attributable fractions of risk in Caucasians were estimated to be 
9% for CLU, 9% for PICALM, 4% for CRl and 4% for BINI. 
The Alzheimer' s Disease Genetics Consortium was formed in 2009 as a collaborative 
effort to understand the genetic underpinnings of AD. The consortium published a large 
meta-analysis in 2011 of several studies spanning over 10000 AD patients and age-
matched controls. This study replicated the previously found genome-wide hits in other 
consortia and gave evidence of four more genes conferring AD risk. This study is 
described in detail in Chapter 3. 
1.4.3 Epistasis in AD 
Typical candidate gene-based and GWA approaches to find disease risk factors examine 
genes individually or by forming haplotypes of neighboring loci. These methods 
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hypothesize that genes confer disease risk through independent marginal contributions to 
trait variability [56]. Genetic association studies have been criticized for being 
inconsistent and failing to replicate across studies [57-59]. Meta-analyses show that 
initially proposed genetic associations for a range of medical outcomes are often refuted 
by subsequent evidence: in one survey of 55 meta-analyses, only 16% of genetic 
associations identified were confirmed, without heterogeneity or bias [ 60]. These 
inconsistencies may be explained by the presence of false-positives and false-negatives or 
due to true differences between populations. 
There have been claims of over 100 epistatic effects in AD in the literature [ 61] based on 
genetic and functional studies, implicating four major pathways: 
a) Cholesterol Metabolism: Regulation of A~ has been linked to cholesterol 
metabolism[ 62]. Protective effects of cholesterol lowering drugs, statins, have been 
observed in some observational studies [63]. Evidence of epistatic effects between 
cholesterol and APOE, the main recognized risk factor for late onset AD has been found 
in the AD pathway[64] . Many cholesterol-related genes have also been associated with 
AD [65] . 
b) Metabolism of A~: Proteolysis ofthe amyloid precursor protein (APP) results in~- and 
y-secretase enzymatic activities producing A~. Epistasis has been observed in genes 
involved in encoding for these enzymes [ 66]. ~-Secretase is identified as the ~-site APP 
cleaving enzyme (BACE1), a membrane-bound aspartyl protease. The main components 
of the y-secretase complex are the presenilins (PS), presenilin enhancer 2 (PEN2), 
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nicastrin (NCSTN) and anterior pharynx defective- I (APHl). While A~ generation and 
aggregation are rather well known, its degradation and clearance have been less 
extensively studied [66]. 
c) Inflammatory Pathways: Inflammatory processes are believed to play a role in the 
pathogenesis of AD. Protective effects of prolonged usage of non steroidal anti-
. 
inflammatory drugs in AD have been reported [67]. Activation of microglia is a central 
part of the chronic inflammatory processes associated with A~ plaques in AD. Activated 
microglia and other brain cells produce and release various inflammatory mediators in 
AD, including cytokines, chemokines, adhesion molecules, activated complement proteins 
and acute-phase reactants [68]. The balance between pro- and anti-inflammatory cytokines 
determines the magnitude of this inflammatory response. Pro-inflammatory cytokines 
include interleukins-lA, lB and 6, and tumor necrosis factor-a; anti-inflammatory 
cytokines include interleukin-1 0 and transforming growth factor-~ 1. AD patients 
displayed a more pro-inflammatory interleukin-6 (IL-6) and less anti-inflammatory IL-l 0 
profile than controls in a blood stimulation assay with endotoxins [69], which might 
reflect similar effects across the blood-brain barrier. 
d) Oxidative Stress Pathway: Oxidative stress is believed to be an early event with an 
important role in the development of AD [70]. There is evidence of oxidative damage in 
AD, particularly to neuronal lipids, but also to proteins, RNA and DNA, including 
mitochondrial DNA [71]. 
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Chapter 2: Shapley Value in Co-operative game theory and application to epistasis 
2.1 Introduction 
Game Theory is a mathematical theory dealing with models for studying interaction 
among decision makers (which are called players). Decision problems that involve a 
single decision maker are not usually considered to be in the domain of application of 
Game Theory. The seminal book by John von Neumann and Oskar Morgenstern (1944) 
'Theory of Games and Economic Behavior' laid down the foundations of Game Theory 
and classified the theory into non-cooperative and cooperative games. Non-cooperative 
game theory specifies a game by defining the strategic environment which includes the 
order of moves, the set of actions at each move and consequently the payoffs for all 
possible plays. Non-cooperative games model situations with conflict where non-binding 
agreements can be made amongst the players. Actions by players can be simultaneous (for 
instance the rock, paper, scissors' game) or at several points in time (for instance the game 
of chess). 
In contrast, cooperative games deal with situations where all kinds of agreements are 
possible amongst players. Such agreements bring players acting in concert and are called 
coalitions. In cooperative games, the decisions are made solely on payoff opportunities 
(conveyed by a single real number) available to each coalition; the sequences of moves, 
actions and individual payoffs are ignored. In cooperative games coalitions coordinate 
their actions with the objective to end up in joint payoffs which often exceed the sum of 
individual payoffs. Coalitional-form games are useful in modeling real-life situations 
where such a structure has proved more tractable than that of a non-cooperative game, 
either in a normal or extensive form. 
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Another important classification in Game Theory can be made based on the goals of the 
analysis performed using its tools. A game, both non-cooperative and cooperative, can be 
analyzed with the objective to indicate what players should do in the game to maximize 
their profits. Usually this goal is referred to as the 'informative approach'. Another reason 
for using Game Theory is to predict the outcome of game, i.e. whether or not players 
optimize their profits (usually referred to as the 'predictive approach'). 
2.2 Shapley's Solution 
Cooperative game theory introduces the concept of "coalitional games", in which a set of 
players is associated with a payoff, a real function that denotes the benefit achieved by 
different sub-coalitions in a game. Formally, a coalitional game is defined by a pair (N,v), 
where N={ 1 ,2,3 ... . n} is the set of all players and v(S) for every S~N is a real number 
associating a worth (value) with the coalition S. Game theory further pursues the question 
of representing the contribution of each player to the game by constructing a value 
function, which assigns a real-value to each player. The values correspond to the 
contribution of the players in achieving a high payoff. 
The contribution value calculation is based on the Shapley Value [72]. An intuitive 
example of the potential use of the Shapley Value can be provided in an academic setting. 
Assume that you are a Professor running a lab and you have decided to distribute the 
yearly bonus to your students in a fair manner that reflects the actual contribution of each 
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student to the academic success of the lab. During the year, the students form spontaneous 
"coalitions" of groups of students, each such group works and publishes a paper 
summarizing its work (these coalitions may also be assembled by the Professor). Every 
paper gets a rank, (example, its impact factor), assigning its "payoff function". Based on 
this annual data of the students' coalitions and their associated payoffs, the Shapley value 
provides a fair and efficient way to distribute the bonus to each individual student 
according to his/her contribution over the year. The Shapley value is defined as follows. 
Let the marginal importance of player ito a coalition S with i not belonging to S be: 
L1i(S) = v(S U {i})- v(S) 
[Equation 2.1] 
The Shapley value is defmed by the payoff 
<l>i (v) = 2._ ~ 4· (S· (n)) 
n! L I I 
nell 
[Equation 2.2] 
where IT is the set of all permutations over N and Si(IT) is the set of players appearing 
before the i1h player in permutation S. The Shapley value of a player is a weighted mean of 
its marginal value, averaged over all possible subsets of players. 
2.3 Game Notation and Definition 
a) Framework of a Coalitional form game 
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A coalitional form game (henceforth game) is defined by a pair (N, v). N denotes a finite 
set of players N = { 1, 2, 3 ... , n} and v is the corresponding characteristic function that 
maps the set of all coalitions 2N to the set of real numbers R and v( ¢) = 0. 
b) Payoff for a coalition 
A group of players SeN is called a coalition and v(S) represents the total payoff or rent 
the coalition S can gain in the game. 
c) The value 
A value is an operator¢ that assigns to each game v a vector of payoffs <f>(v) =(¢1,¢2, ... , 
<f>n) in Rn. <f>i(v) stands fori ' s payoff in the game, or alternatively for the measure ofi ' s 
power in the game. 
d) Shapley value 
Shapley presented the value as an operator that assigns an expected marginal contribution 
to each player in the game with respect to a uniform distribution over the set of all 
permutations on the set of players. Specifically, let n be a permutation (or an order) on the 
set of players, i.e., a one-to-one function from N onto N, and let us imagine the players 
appearing one by one to collect their payoff according to the order n. For each player i we 
can denote by p n i = {j: 1t (i) > 1t G)} the set of players preceding player i in the order n. 
The marginal contribution of player i with respect to that order n is v(p 1t i u i) - v(p 1t i). 
Now, if permutations are randomly chosen from the set IT of all permutations, with equal 
probability for each one of the n! permutations, then the average marginal contribution of 
player i in the game v is 
__ 1' 
n! L 
n=IT 
[Equation 2.3], which is Shapley's definition of the value. 
Another version of the Shapley value cp on Vis given by 
cl>i(v) Ls~N\{i} lSI! (n - lSI - 1)! 
n! 
V v E V and Vi E N [Equation 2.4] 
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(v(S u {i}) - v(S)) 
Shapley gives the following interpretation of equation 2.4 [72] : "The players inN agree to 
play the game v in a grand coalition, formed in the following way: 1. starting with a single 
member, the coalition adds one player at a time until everybody has been admitted. 2. The 
order in which the players are to join is determined by chance, with all arrangements 
equally probable. 3. Each player, on his admission, demands and is promised the amount 
which his adherence contributes to the value of the coalition (as determined by the 
function v). The grand coalition then plays the game "efficiently" so as to obtain v(N)-
exactly enough to meet all the promises." 
e) Simple games 
Simple games are defined such that the worth of each coalition is either a 0 or 1. A w( s) = 
1 is a winning coalition. Simple games provide a suitable model for situations involving 
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exercise of power in voting games and a measure of the influence of a coalition of players 
in deciding an outcome. Formally, a coalitional game (N,w) such that w: 2N ----+[0, 1] is 
called a [0, 1]-game. We will denote the class of all [0, 1]-games as W, with WcG, G 
being the class of all coalitional games. Simple games provide a useful framework for 
analyzing interactions between genes in the context of dichotomous phenotypes. A 
simple-game framework would assume that a coalition of genes either cause the 
phenotype of interest or not. It won' t model situations where a group of genes might 
influence disease severity more or less than another group of genes. 
f) Unanimity games 
In some simple games a particular coalition Tis necessary and sufficient to form a 
winning coalition, so that, 
w(S) = 1, if S::JT and 0 otherwise, [Equation 2.5] 
Each member i of the essential coalition Tis called a veto player, since no winning 
coalition can be formed without i. The game is called a unanimity game, since winning 
requires the collaboration of all veto players. 
For a given set of players N, each coalition T defines a different unanimity game 1-LT given 
by 
J..LT(S) = 1, if S::JT and 0 otherwise, [Equation 2.5] 
Important Property of Unanimity games 
Every coalitional game (N, v) can be written as a linear combination of unanimity games 
in a unique way, i.e., v =IT~N and S;<<I> AT(v)uT (see, for instance, Owen 1995). The 
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coefficients AT(v), for each T E 2N \ {(2)}, are called unanimity coefficients of the game (N, 
v) 
Hence, an alternative representation of the Shapley value can be given in terms of the 
unanimity coefficients (AT(v))TE2N\{ 0} of a game (N, v), that is: 
4>i(v) I AT(v) T~N:iES ITI 
ViE N (equation [2.6]) 
2.4 Calculation of Shapley Value to rank genes for interaction 
Note: Adapting the mathematical foundation of the problem, first laid out by Moretti et al 
[73} for mircroarray chip data, I adapt their representation of the problem to handle 
genetic association data. 
Let N = {1, 2, . .. , n} be a set ofn SNPs, and letS= {S1, S2, S3 .... . Sm} be the set ofM 
subjects in a GWAS study. A section of the data from the study might look like: 
Case Case Control Control Case Control 
SNP Sl S2 S3 S4 S5 S6 
rsl AA AG GG GG AG AG 
rs2 TT TT cc TC TT TC 
rs3 cc GG GG CG cc GG 
rs4 GG GG CG cc GG GG 
The data contains 4 SNPs genotyped in 6 subjects, subjects 1,2 and 5 are affected and 
subjects 3,4 and 6 are unaffected for the phenotype. 
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As a first step, I am interested in whether a SNP is able to contribute to the prediction of 
case/control status on the basis of the presence or absence of an allele or genotype. If the 
phenotype were Mendelian in nature and the causal SNP was fully penetrant, being 
homozygous for the risk allele will predict a positive phenotype and being homozygous 
for the protective allele will predict a negative phenotype. Using this paradigm, we 
evaluate for every SNP, the risk and protective alleles. The risk allele is simply the allele 
that has a higher frequency in cases versus controls. As an example, let us defme two 
discriminant functions that convert the above data into two risk matrices BiJ E { 0, 1, 2} 
where i is the number of SNPs and j is the number of samples. 
Discriminant Function 1: Additive Discriminant Function 
"genotype k E {aa, aA, AA} of SNP i EN for sample j EM gets coded as 2 if it is 
homozygous for the risk allele in j has the phenotype (is a case subject) OR if it 
homozygous for the protective allele and j does not have the phenotype (is a control 
subject), and 1 if heterozygous and zero otherwise" 
Discriminant Function 2: Dominant/Recessive Discriminant Function 
"genotype k E {aa, aA, AA} of SNP i EN for sample j EM gets coded as 2 if it is 
homozygous for the risk allele and j has the phenotype (is a case subject) OR if it 
homozygous for the protective allele and j does not have the phenotype (is a control 
subject) and zero otherwise" 
23 
Note: The allele with a higher frequency in cases compared to controls is assigned as the 
risk allele for a SNP in the above representations. 
The discriminant function aims to determine if a SNP genotype contributes positively 
towards the predicting the phenotype or not. A discriminant method can be expressed as a 
map m assigning the subject's genotype across all SNPs, a corresponding Risk expression 
profile. The profile lists the SNPs that contribute positively towards predicting the 
sample's phenotype. 
1.) Additive Discriminant Function 
S1 S2 S3 S4 S5 
rs1 2 1 2 2 1 
rs2 2 2 2 1 2 
rs3 2 0 2 1 2 
rs4 2 2 1 2 2 
2.) Dominant/Recessive Discriminant Function 
S1 S2 S3 S4 S5 
rs1 1 0 1 1 0 
rs2 1 1 1 0 1 
rs3 1 0 1 0 1 
rs4 1 1 0 1 1 
S6 
1 
1 
2 
0 
S6 
0 
0 
1 
0 
Risk Allele A 
Risk Allele T 
Risk Allele C 
Risk Allele G 
Risk Allele A 
Risk Allele T 
Risk Allele C 
Risk Allele G 
Based on the two discriminant functions defined earlier, the data will be converted into 
0/112 or 0/1 matrices as shown above. For reasons explained in Chapter 4 that we'll use 
the additive discriminant function in the rest of the manuscript. For the rest of the 
illustration we'll use the additive coding example. 
The matrix obtained is defmed as: 
1 
2 
0 
2 
2 
2 
2 
1 
2 
1 
1 
2 
1 
2 
2 
2 ~) [Matrix 2.1] 
The model can be interpreted as each SNP having two votes towards predicting the 
phenotype (one vote in case ofthe dominant coding). 
Sufficiency principle of SNPs 
In this phase of the analysis we assume that the Risk expression profile BG) for each 
sample j E S, is a sufficient condition for the onset of the disease. In other words, the 
SNPs for a subject having the risk genotype are sufficient to predict the presence or 
absence of the disease in that subject. This assumption could be violated under some 
conditions; there could be SNPs absent in the GWAS which might explain some of the 
risk of the phenotype, or environmental factors might affect the onset of the disease or 
genotyping error could misclassify a SNP as risk causing. 
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The aim of the analysis is to assign a relevance index to the SNPs in predicting the disease 
status of an individual. The algorithm will try to measure the power ofthe SNPs in 
determining the phenotype of a sample in the presence of other SNPs influencing the risk 
of the disease. In order to use Shapley value to measure the relevance index of SNPs, two 
definitions are required: 
Definition 1: Let WE {0, 1}N, n E {1, 2, .. . }. The support ofW, denoted by sp(W), is 
defined by the set sp(WJ = { i E { 1, .. . , n} I Wi =1:- 0}. In our context, the support of a 
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sample is defined as the group of SNPs that have a 1 or a 2 for that sample. The support 
set of a "subject" is the coalition of SNPs that combine to predict its phenotype. For 
example: sp (S1) = {1,2,3,4} from the Matrix 1. 
Definition 2: Let B be a Risk matrix [Matrix 1] obtained from our GWAS data and the 
additive discriminant function described above. We describe a coalitional game (N,v) on 
the our data such that: 
• The set of SNPs N is the set of players. 
• The characteristic function (or payoff function) v assigns to each coalition T E 2N \ { {tJ} 
the average number of samples whose phenotype was determined by T according to the 
sufficiency principle for groups of genes. 
Formally, v(T) V T E 2N \ {0}, 
v(T) 
[Equation 2. 7] 
,where J0rl is the cardinality of the set 
E>(T) = {k E S I sp(B(k) )c T, sp(B(k):;t:<f>} 
26 
[Equation 2.8] 
Recalling the property of unanimity games from Equation 2.6, we can rewrite equation 2.7 
as 
v = l~l I Usp(B(j)) 
jES:sp(B(j):;t:<J> 
, where Usp(B(j)) is the unanimity game on sp(BG)) eN, V j E S. 
[Equation 2.9] 
Writing equation 2.8 in terms of unanimity coefficients we get 
v(T) 
where f..t =f../ I lSI, "A1* is the number of occurrences of the coalition t as support in the 
Risk matrix B. 
[Equation 2.10] 
From equation 2.3 and equation 2.10, the Shapley value of SNP i in the GWAS game can 
be written as: 
ct>i(v) 1 I AT* 
s T~N:iET ITI 
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for each i EN 
[equation 2.11] 
Equation 2.11 is used to calculate the Shapley value of every SNP in the GWAS study 
which determines the relevance index of a SNP in predicting the phenotype in the 
presence of other SNPs. The computation of the Shapley value <f>(v) is straightforward 
from Equation 2.11 and does not require evaluating all possible coalitions because of the 
sufficiency principle assumption. The complexity of evaluation of the Shapley Value for 
the defined GW AS game follows O(N*M) where N is the number of genes and M is the 
number of subjects in the study. 
An example ofthe Shapley Value calculation is illustrated below: 
The Risk Matrix defmed in [Matrix 1] was: 
B = (~ 1 2 0 
2 
2 2 1 
2 1 2 
2 1 2 
1 2 2 
To calculate the Shapley Value for every SNP, we use the sufficiency principle; for 
subject 1 (column 1) all4 SNPs are required to determined the phenotype status. For 
subject 2 SNPs 1, 2 and 4 are sufficient to determine the disease status and so on. 
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Hence the Unanimity Game defined on subject 1 requires that for any coalition to predict 
the disease, subject 1 will require all4 SNPs; for subject 2 the winning coalition requires 
SNPs 1, 2 and 4; for subject 3, all SNPs are in the winning coalition and so on. 
From equation 2.1 0, for the Risk Matrix B, the corresponding game ( { 1 ,2,3,4}, v) can be 
defined as 
1 
v = 6 ( u (1,2,3,4) + u (1,2,4) + u(1,2,3,4) + u(1,2,3,4) + u(1,2,3,4) + u (1,2,3) 
It follows that v(1)=v(2)=v(3)=v(4)= v(1,2)= v(1,3)= v(1,4)= v(2,3)= v(2,4)= v(3,4)= 
v(2,3,4)=0, implying that {1} alone, {2} alone, {3} alone, {4} alone, {1, 2} alone, {1, 3} 
alone ... {2, 3, 4} alone are not sufficient to predict the disease in any subject 
Also, v(1 ,2,3) = v(2,3,4)= 1/6, implying that coalitions {1,2,3} and {2,3,4},can predict the 
disease in one of the 6 individuals 
And finally v(1,2,3,4) = 1 implying the coalition of all the SNPs in the GWAS can predict 
the disease status in all the subjects which was the defmition of the sufficiency principle. 
The Shapley value of SNP 1 will be the average sum of its marginal contributions across 
all possible coalitions {1}, {1,2}, {1,3}, {1,4}, {1,2,3} ..... {1,2,3,4}. From the above 
illustration only coalitions sufficient to predict the disease in every subject get a value 
greater than zero. Hence a quick way to calculate the Shapley Value is to find the 
contribution of every SNP to a winning coalition in every subject separately and sum 
across all subjects for a SNP. For example the Risk Matrix B can be reduced to a Shapley 
Matrix 
(2/8 1/5 2/7 2/6 1/7 1/4) 
Sh = 2/8 2/5 2/7 1/6 2/7 1/4 
2/8 0 2/7 1/6 2/7 2/4 
2/8 2/5 1/7 2/6 2/7 0 
Note: The denominators for the Sh matrix represent the sum of votes for each subject 
The Shapley Value for each SNP will be the sum across all subjects divided by the total 
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number of subjects (from equation 2.11 ). Hence the Shapley Value for the above matrix is 
<J>(v) = (0. 26, 0. 27, 0. 31, 0. 16) 
From the Shapley Value, we infer that SNP 3 has the highest relevance on average in 
predicting the disease followed by SNPs 2, land 4. 
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Chapter 3: The Alzheimer Disease Genetics Consortium (ADGC) data 
The contents of this chapter are taken from Naj et al [74]. Here, we describe the ADGC datasets 
used to find interactions associated with AD. We also described the protocol to clean the datasets 
to retain high quality SNPs for prioritizing and testing interactions. 
3.1 Introduction 
To identify genetic variants associated with risk for Alzheimer's disease, the Alzheimer's 
Disease Genetics Consortium (ADGC) assembled a discovery dataset (stage 1, 8,309 indi-
viduals with late-onset AD (cases) and 7,366 cognitively normal elders (CNEs) as 
controls) using data from eight cohorts and a ninth newly assembled cohort from the 29 
National Institute on Aging (NIA)-funded Alzheimer Disease Centers (ADCs) (Table 
3.1.a and 3.1.b). The data sets were coordinated by the National Alzheimer Coordinating 
Center (NACC) and samples coordinated by the National Cell Repository for Alzheimer 
Disease (NCRAD). For the stage 2 replication, we used four additional datasets and addi-
tional samples from the ADCs (3 ,531 LOAD cases and 3,565 CNEs). The stage-3 
replication used the results of association analyses provided by three other consortia, 
including 6,992 LOAD cases and 24,666 mixed-age controls, reported in a companion 
manuscript [75]. For the purpose of testing interactions associated with AD, we used 13 
case-control datasets (ACT, ADCl , ADC2, ADC3 , ADNI, WU, GENADA, U PENN, 
OHSU, MAYO, UMIMSSMNU, ROSIMAP and TGEN; datasets described below) to 
prioritize SNP-pairs to be tested for interaction using the Shapley Value Algorithm. We 
used the entire ADGC dataset (15 GWAS studies including NIA-LOAD and MIRAGE) 
for replication of and further analysis of significant SNP-pairs. 
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3.2 ADGC Data 
3.2.1 Description of the Datasets 
Tables 3.2.a and 3.2.b provide a detailed description of the datasets. The ADGC dataset 
used in this analysis comprises of 15 studies-subjects from the Adult Changes in Thought 
(ACT)/ Electronic Medical Records and Genetics (eMERGE) study, the National 
Institute on Aging (NIA) Alzheimer Disease Centers (ADCs), the Alzheimer Disease 
Neuroimaging Initiative (ADNI) Study, the Multi-Site Collaborative Study for Genotype-
Phenotype Associations in Alzheimers Disease (GenADA) Study, the University of 
MiamiN anderbilt University/Mt. Sinai School of Medicine (UMNU/MSSM), the 
MIRAGE Study, Oregon Health and Science University (OHSU), the NIA-LOAD Study, 
the Translational Genomics Research Institute series 2 (TGEN2) dataset, the Mayo 
Clinic, the Rush University Religious Orders Study/Memory and Aging Project 
(ROSMAP), the University of Pittsburgh (UP), and Washington University (WU). 
Detailed descriptions of the ascertainment and evaluation of subjects in the ADC, ADNI, 
UMNU/MSSM, MIRAGE, and NIA-LOAD cohorts have been provided elsewhere[76]; 
brief descriptions included here note any differences between data used in this study and 
data used in the previously published ADGC study[76]. We restricted analyses to 
individuals of European ancestry because there were an insufficient number of subjects 
from other ethnic groups to obtain meaningful results especially for interaction analyses. 
All data from members of other ethnic groups examined in our prior publication were not 
evaluated here. We describe here in more detail the novel cohorts including those from 
the ACT/eMERGE Study, the GenADA Study, TGEN2, the Mayo Clinic, ROS/MAP, 
UP, and WU. All subjects were recruited under protocols approved by the appropriate 
Institutional Review Boards. 
32 
The NIA ADC Samples (ADC): The NIA ADC cohort included subjects ascertained 
and evaluated by the clinical and neuropathology cores of the 29 NIA-funded ADCs. 
Data collection is coordinated by the National Alzheimer' s Coordinating Center (NACC). 
NACC coordinates collection of phenotype data from the 29 ADCs, cleans all data, 
coordinates implementation of definitions of AD cases and controls, and coordinates 
collection ofDNA samples. The ADC cohort consists of2,288 autopsy-confirmed and 
913 clinically-confirmed AD cases, and 519 cognitively normal elders (CNEs) with 
complete neuropathology data who were older than 60 years at age of death, and 7 44 
living CNEs evaluated using the Uniform dataset (UDS) protocol [77, 78] who were 
documented to not have mild cognitive impairment (MCI) and were between 60 and 1 00 
years of age at assessment. 
Based on the data collected by NACC, the ADGC Neuropathology Core Leaders 
Subcommittee derived inclusion and exclusion criteria for AD and control samples. All 
autopsied subjects were age 2: 60 years at death. AD cases were demented according to 
DSM-IV criteria or Clinical Dementia Rating (CDR) 2: 1. 
Neuropathologic stratification of cases followed NIA/Reagan criteria explicitly, or used a 
similar approach when NIA/Reagan criteria[79] were coded as not done, missing, or 
unknown. Cases were intermediate or high likelihood by NIA/Reagan criteria with 
moderate to frequent amyloid plaques[80]and neurofibrillary tangle (NFT) Braak stage of 
III-VI[81, 82]. Persons with Down's syndrome, non-AD tauopathies and 
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synucleinopathies were excluded. All autopsied controls had a clinical evaluation 
within two years of death. Controls did not meet DSM-IV criteria for dementia, did not 
have a diagnosis of mild cognitive impairment (MCI), and had a CDR of 0, if performed. 
Controls did not meet or were low-likelihood AD by NIA/Reagan criteria, had sparse or 
no amyloid plaques, and a Braak NFT stage of 0 - II. 
ADCs sent frozen tissue from autopsied subjects and DNA samples from some autopsied 
subjects and from living subjects to the ADCs to the National Cell Repository for 
Alzheimer's Disease (NCRAD). DNA was prepared by NCRAD for genotyping and sent 
to the genotyping site at Children' s Hospital of Philadelphia. ADC samples were 
genotyped and analyzed in separate batches. 
While most neuropathologically- and clinically-characterized cases and CNEs were 
included in two waves included in the Discovery dataset (ADCl and ADC2), a third 
wave of clinically-identified living cases and CNEs (ADC3) were incorporated into the 
replication dataset and are described in more detail below. ADCl and ADC2 contributed 
2,304 AD cases (1,761 autopsy-confirmed; 543 clinically-confirmed) and 675 CNEs (515 
autopsy-confirmed; 160 clinically-confirmed), of which 1,595 autopsied-confirmed AD 
cases and 132 CNEs were analyzed in our previous study [76]. 
Oregon Health and Science University (OHSU): The OHSU dataset includes 132 
autopsy-confirmed AD cases and 153 deceased controls that were evaluated for dementia 
within 12 months prior to death (age at death> 65 years). These individuals are a subset 
ofthe 193 cases and 451 controls examined in our previous study [76] meeting more 
stringent QC criteria in this study. Subjects were recruited from aging research cohorts at 
10 NIA-funded ADCs and did not overlap other samples assembled by the ADGC. A 
more extensive description of control samples can be found elsewhere [83]. 
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The ADNI Study (ADNI): ADNI is a longitudinal, multi-site observational study 
including AD, mild cognitive impairment (MCI), and elderly individuals with normal 
cognition assessing clinical and cognitive measures, MRI and PET scans (FDG and 11 C 
PIB) and blood and CNS biomarkers. For this study, ADNI contributed data on 268 AD 
cases with MRI confirmation of AD diagnosis and 173 healthy controls with AD-free 
status confirmed as of most recent follow-up. AD subjects were between the ages of 55-
90, had an MMSE score of 20-26 inclusive, met NINCDS/ ADRDA criteria for probable 
AD[84] , and had an MRI consistent with the diagnosis of AD. Control subjects had 
MMSE scores between 28 and 30 and a Clinical Dementia Rating of 0 without symptoms 
of depression, MCI or other dementia and no current use of psychoactive medications. 
According to the ADNI protocol, subjects were evaluated at regular intervals over 3 
years. For the purpose of our analysis we only used the final ascertainment status to 
classify case-control status. Additional details of the study design are available 
elsewhere [76, 85, 86]. 
The MIRAGE Study (MIRAGE): The MIRAGE study is a family-based genetic 
epidemiological study of AD that enrolled AD cases and unaffected sibling controls at 1 7 
clinical centers in the United States, Canada, Germany, and Greece (details 
elsewhere[87]), and contributed 1,262 subjects (509 AD cases and 753 CNEs), a subset 
of the 559 cases and 788 controls that were incorporated into our prior study[76] which 
met more stringent QC criteria for this study. Briefly, families were ascertained through 
a proband meeting the NINCDS-ADRDA criteria for definite or probable AD. 
Unaffected sibling controls were verified as cognitively healthy based on a Modified 
Telephone Interview of Cognitive Status score~ 86[88]. 
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The NIA LOAD Family Study (NIA-LOAD): The NIA LOAD Family Study[89] 
recruited families with two or more affected siblings with LOAD and umelated, CNEs 
similar in age and ethnic background. A total of 1,819 cases and 1,969 CNEs from 1,802 
families were recruited through the NIA-LOAD study, NCRAD, and the University of 
Kentucky and included for analysis, ofwhich a subset of985 cases and 881 controls were 
used in the previous study[76]. One case per family was selected after determining the 
individual with the strictest diagnosis (definite> probable> possible LOAD). If there 
were multiple individuals with the strictest diagnosis, then the individual with the earliest 
age of onset was selected. The controls included only those samples that were 
neurologically evaluated to be normal and were not related to a study participant. 
University of Miami/Vanderbilt University/Mt. Sinai School of Medicine 
(UMNU/MSSM): The UMNU/MSSM dataset contains 1,186 cases and 1,135 CNEs 
(new and previously published)[49, 90-92] ascertained at the University of Miami, 
Vanderbilt University and Mt. Sinai School of Medicine, including 409 autopsy-
confirmed cases and 136 controls, primarily from the Mt. Sinai School ofMedicine[93]. 
An additional 16 cases were included and 34 controls excluded from the data analyzed in 
the prior study[76]. Each affected individual met NINCDS-ADRDA criteria for probably 
or defmite AD with age at onset greater than 60 years as determined from specific probe 
questions within the clinical history provided by a reliable family informant or from 
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documentation of significant cognitive impairment in the medical record. Cognitively 
healthy controls were unrelated individuals from the same catchment areas and frequency 
matched by age and gender, and had a documented MMSE or 3MS score in the normal 
range. Cases and controls had similar demographics: both had ages-at-onset/ages-at-
exam of74 (± 8 standard deviations), and cases were 63% female, and controls were 61% 
female. 
The ACT/eMERGE Studies (ACT): The ACT cohort is an urban and suburban elderly 
population from a stable HMO that includes 2,581 cognitively intact subjects age~ 65 
who were enrolled between 1994 and 1998[94, 95]. An additional 811 subjects were 
enrolled in 2000-2002 using the same methods except oversampling clinics with more 
minorities. More recently, a Continuous Enrollment strategy was initiated in which new 
subjects are contacted, screened and enrolled to keep 2000 active at-risk person-years 
accruing in each calendar year. This resulted in an enrollment of 4,146 participants as of 
May 2009. All clinical data are reviewed at a consensus conference. Dementia onset is 
assigned half way between the prior biennial and the exam that diagnosed dementia. 
Enrollment for eMERGE Study began in 2007. A waiver of consent was obtained from 
the IRB to enroll deceased ACT participants. In total, ACT/eMERGE contributed data 
on 566 individuals with probable or possible AD (70 with autopsy-confirmation) and on 
1,696 CNEs (155 with autopsy-confirmation) who were included in analyses. 
The GenADA Study: Data from the GenADA cohort that were analyzed included 669 
AD cases and 713 CNEs ascertained from nine memory referral clinics in Canada 
between 2002 and 2005. Patients and CNEs were of Caucasian ancestry from Northern 
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Europe. All patients with AD satisfied NINCDS-ADRDA and DSM-IV criteria for 
probable AD with Global Deterioration Scale scores of3-7. CNEs had MMSE test 
scores higher than 25 (mean 29.2 ± 1.1), a Mattis Dementia Rating Scale score of ~ 136, 
a Clock Test without error, and no impairments on seven instrumental activities of daily 
living questions from the Duke Older American Resources and Services Procedures test. 
Data were collected under an academic-industrial grant from Glaxo-Smith-Kline, Canada 
by Principal Investigator P. StGeorge-Hyslop. Detailed characteristics of this cohort 
have been described previously[ 51]. 
The TGEN2 Study: Among the TGEN2 data analyzed were 864 clinically- and 
neuropathologically-characterized brain donors, and 493 CNEs without dementia or 
significant AD pathology. Of these cases and CNEs, 667 were genotyped as a part of the 
TGENl series[ 52] . Samples were obtained from twenty-one different National Institute 
on Aging-supported AD Center brain banks and from the Miami Brain Bank as 
previously described[52, 96, 97]. Additional individual samples from other brain banks in 
the United States, United Kingdom, and the Netherlands were also obtained in the same 
manner. The criteria for inclusion were as follows: self-defined ethnicity of European 
descent, neuropathologically confirmed AD or neuropathology present at levels 
consistent with status as a control, and age of death greater than 65 . Autopsy diagnosis 
was performed by board certified neuropathologists and was based on the presence or 
absence of the characterization of probable or possible AD. Where it was possible, Braak 
and Braak staging and/or CERAD classification were employed. Samples derived from 
subjects with a clinical history of stroke, cerebrovascular disease, comorbidity with any 
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other known neurological disease, or with the neuropathological finding of Lewy bodies 
were excluded. 
The ADC3 dataset 
The ADC3 dataset contains 897 clinically-identified living cases (527 with autopsy-
confirmation) and 588 CNEs (4 with autopsy-confirmation) who were genotyped 
between July and August 2010, and were ascertained similarly to ADC1 and ADC2 as 
previously described. No ADC3 data were examined in the previous publication ofthe 
ADGC[76]. 
Mayo Clinic: All 728 cases and 1,173 controls consisted of Caucasian subjects from the 
United States ascertained at the Mayo Clinic. All subjects were diagnosed by a 
neurologist at the Mayo Clinic in Jacksonville, Florida or Rochester, Minnesota. The 
neurologist confirmed a Clinical Dementia Rating score of 0 for all controls; cases had 
diagnoses of possible or probable AD made according to NINCDS-ADRDA criteria[84]. 
Autopsy-confirmed samples (221 cases, 216 CNEs) came from the brain bank at the 
Mayo Clinic in Jacksonville, FL and were evaluated by a single neuropathologist. In 
clinically-identified cases, the diagnosis of definite AD was made according to NINCDS-
ADRDA criteria[84]. All AD brains analyzed in the study had a Braak score of 4.0 or 
greater. Brains employed as controls had a Braak score of 2.5 or lower but often had 
brain pathology unrelated to AD and pathological diagnoses that included vascular 
dementia, frontotemporal dementia, dementia with Lewy bodies, multi-system atrophy, 
amyotrophic lateral sclerosis, and progressive supranuclear palsy. 
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The ROS/MAP Studies: ROS/MAP are two community-based cohort studies. The 
ROS has been on-going since 1993, with a rolling admission. Through July of2010, 
1,139 older nuns, priests, and brothers from across the United States initially free of 
dementia who agreed to annual clinical evaluation and brain donation at the time of death 
completed their baseline evaluation. The MAP has been on-going since 1997, also with a 
rolling admission. Through July of2010, 1,356 older persons from across northeastern 
Illinois initially free of dementia who agreed to annual clinical evaluation and organ 
donation at the time of death completed their baseline evaluation. Details of the clinical 
and neuropathologic evaluations have been previously reported[98-101]. A total of 1,072 
persons passed genotyping QC. Of these, 296 met clinical criteria for AD at the time of 
their last clinical evaluation or time of death and met neuropathologic criteria for AD for 
those on whom neuropathologic data were available, and 776 were without dementia or 
MCI at the time of their last clinical evaluation or time of death and did not meet 
neuropathologic criteria for AD for those on whom neuropathologic data were available. 
University of Pittsburgh (UP): The University of Pittsburgh dataset contains 1,271 
Caucasian AD cases (of which 277 were autopsy-confirmed) recruited by the University 
of Pittsburgh Alzheimer's Disease Research Center, and 841 Caucasian, CNEs ages 60 
and older (2 were autopsy-confirmed). All AD cases met NINCDS/ADRDA criteria for 
probable or defmite AD. Additional details ofthe cohort used for GW AS have been 
previously published[ I 02]. 
Washington University (WU): A European American LOAD case-control dataset 
consisting of339 cases and 187 healthy elderly controls was used in analyses for this 
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study. Participants were recruited as part of a longitudinal study of healthy aging and 
dementia. Diagnosis of dementia etiology was made in accordance with standard criteria 
and methods [78]. Severity of dementia was assessed using the Clinical Dementia Rating 
scale. 
3.2.2 Quality Control and Analysis Methods 
Genotyping and Data Cleaning 
All cohorts were genotyped using either Illumina or Affymetrix high-density SNP 
microarrays (Table 3.2.b). To optimize quality of genotyping data, we applied pre-
determined cutoffs of call rates and minor allele frequencies to each cohort individually. 
Prior to analysis, SNPs with a call rate less than 98% (95% for Affymetrix chips), with a 
minor allele frequency (MAF) less than 0.01 (0.02 for Affymetrix chips), or not in 
Hardy-Weinberg equilibrium (HWE) (P < 1 o-6) were excluded. After excluding SNPs 
that did not meet quality control standards, we excluded individual samples with SNP call 
rates below 95% for Affymetrix arrays or 98% for Illumina arrays among the remaining 
SNPs, or whose gender as determined by analysis ofX-chromosome data (performed in 
the Plink [20] software package) was inconsistent with the reported gender. For cohorts 
genotyped on multiple chips (MIRAGE and UMNU/MSSM), per-SNP and per-subject 
call rates were determined within subsets of individuals genotyped on each chip, as well 
as in the genotype data for all chips combined. Individuals and SNPs in these two cohorts 
were filtered separately based on quality measurements, and then population stratification 
was checked in each cohort using SNPs that were common across chips. 
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Possible relative pairs in the case-control cohorts (ADC, ACT, GenADA, TGEN2, 
UMNU/MSSM, ADNI, ROSMAP, UP, WU, and Mayo Clinic) were identified by 
pairwise genome-wide estimates of identity-by-descent (IBD) using PLINK software[20, 
103]. This analysis yields an overall estimate of relatedness ( Jr) equivalent to P(IBD = 
2) + (0.5 x P(IBD = 1)) or the proportion of IBD. Estimates of the proportion ofiBD 
were categorized as indicating an identical pair ( Jr > 0.99), a related pair (0.4 2: ;r > 
0.90), or an unrelated pair (n < 0.4). Identical samples within a cohort were treated as an 
error, and both subjects were excluded from analysis. One subject from each related pair 
was excluded as follows: if one subject in the pair was missing case status, the data for 
that individual were excluded; if both subjects had non-missing but discordant phenotype 
information, data for both subjects were excluded; if the phenotype data were concordant 
for both subjects, the subject with the lower call rate was excluded. The relatedness 
among individuals in each of the three family-based cohorts (MIRAGE, FHS and NIA-
LOAD) was confirmed via estimates ofiBD sharing proportions across the genome-wide 
set of markers using PREST software[104]. Any discrepancies identified were reviewed 
in light of full clinical and pedigree data available to determine the most likely 
relationship consistent with a proportion of IBD, and any remaining unresolved scenarios 
were excluded from the subsequent analysis. 
We also investigated cross-study identical pairs among cleaned samples using the 
proportion of IBD estimated by Plink software. SNP data from all studies were merged 
and a global test for relatedness was performed. Pairs with 1r > 0.95 were considered 
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duplicate enrollments across studies. Subjects with duplicate enrollments and whose 
case/control status varied across the studies were excluded from analysis in all studies. 
Individuals with concordant phenotypes and duplicate enrollments were included in 
analysis of only one study, selected according to a predetermined priority of cohorts 
which considers genotyping array, genotype quality, phenotype quality, and preference of 
family data. The number of duplicate enrollments and the order of cohorts used in 
selection are summarized in Table 3.2.c. 
APOE genotyping in the ADC, eMERGE and NIA-LOAD datasets was performed by 
Prevention Genetics in which the genotypes were determined based on allelic 
combinations of SNPs rs7412 and rs429358. The same SNPs were genotyped in the 
UMNU/MSSM dataset at the University of Miami Institute for Human Genornics or the 
Vanderbilt University Center for Human Genetics Research, and in the Mayo Clinic 
dataset at the Mayo Clinic in Jacksonville using the ABI 7900 TaqMan system and in the 
GenADA dataset using the ABI 7200 Taqman system. APOE genotypes in the MIRAGE 
cohort were determined using the Roche Diagnostics LightCycler® 480 instrument 
(Roche Diagnostics, Mannheim, Germany)[105] LightMix® Kit ApoE C112R 
R158(Cat.-No. 40-0445-16) from TIB MOLBIOL (http://www.roche-
as.es/logs/LightMix%C2%AE 40-0445-16 ApoE-112-158 V080904.pdf). APOE 
genotypes in TGEN2, ADNI, UP and WU cohorts were obtained by pyrosequencing[106] 
or restriction fragment length polymorphism analysis[107, 108]. APOE genotyping in 
the ROSMAP dataset was performed by Agencourt Bioscience Corporation (Beverly, 
MA) using high-throughput sequencing of codon 112 (position 3937) and codon 158 
(position 4075) of exon 4 of the APOE gene on chromosome 19. 
Imputation procedure 
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We conducted genome-wide imputation with the Markov Chain Haplotyping (MaCH) 
software[109] using reference haplotypes from the CEPH Utah pedigree (CEU) samples, 
comprised of individuals ofNorthern European background, from the HapMap phase 2 
(release 22) database. This procedure also filled in missing data for genotyped SNPs. 
Individuals with high genotyping call rates (>95%) and SNPs with 95% call rates or 
better were used as seeds for the imputation procedure. We excluded SNPs with low 
MAF (<1 %), SNPs not in HWE (P <10-6), and SNPs with potential for undetected strand 
flips (C/G and A/T coding) to ensure consistency of allele frequencies between the test 
and reference haplotypes and to improve the quality of imputation. Imputation quality 
was determined as R2, which estimates the squared correlation between imputed and true 
genotypes. Within each dataset, only SNPs imputed with R2 2: 0.50 were included in 
analysis. 
Covariate Data 
Several datasets measured or collected data on ages of symptom onset (ADC, TGEN2, 
NIA-LOAD, MIRAGE, ACT, GenADA, FHS, UP, ROS/MAP and UMNU/MSSM), 
while others provided only age at ascertainment (ADNI and WU), age at diagnosis (Mayo 
Clinic) or a combination of both age at ascertainment and age at death (a subset of 
autopsy-confirmed samples in the UMIVU/MSSM dataset). For datasets with a 
combination of autopsy-confirmed and clinically-ascertained cases (Table 3.2.a), the age 
44 
at symptom onset was equated to the age at death for subjects ascertained at autopsy. For 
all studies, the age used for CNEs was the age of last exam or age at death. Subjects with 
age at symptom onset or age at death less than 60 were excluded from analysis, 
irrespective of case-control status. 
Statistical Analysis 
Intra-Study Population Substructure 
Several approaches were used to account for within-study population substructure prior 
to association analyses, incorporating strategies used in previously published analyses on 
certain datasets for consistency. To determine if population substructure existed in the 
UMNU/MSSM dataset, 30,000 SNPs with MAF > 0.25 and minimal between-SNP 
linkage disequilibrium(/< 0.20) were sampled at random from the autosomes, and 
analyzed with the Structure software package[11 0, 111] (bum in: 5,000, iterations: 
25,000) assuming different number of subpopulations (K). In this dataset, the -log10 
likelihood for K was maximized at K = 4, suggesting population substructure is present. 
To account for population substructure in association analyses, the EIGENSTRAT[112] 
smartpca script was used to generate loadings from principal components analysis on the 
30,000 SNPs sampled. Up to the top four principal component loadings were included as 
covariates to account for population substructure in the association analyses. These 
analyses were conducted independently for each study. 
For the NIA-LOAD, sets of unrelated individuals were constructed based on self-reported 
ethnic information combined with principal component analysis, as described below. The 
first dataset was drawn from the complete sample of unrelated individuals including all 
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population groups. The sample contained one randomly selected individual from each 
family. These individuals were used for initial investigation of population structure in the 
sample using genotypes from the Illumina panel and the smartpca script implemented in 
the EIGENSTRAT package[112]. Initial cluster analysis was based on a principal 
component analysis (PCA) of the complete unrelated sample, with ethnic-specific 
clusters delineated based on self-declared ethnicity. This initial analysis was used to 
refine the cluster location of the European-American subset within the larger sample, and 
to classify subjects with undeclared ethnicity to define the final sample used for further 
analysis. After excluding self-reported Hispanics that clustered as part of the main 
European-American cluster, individuals self-identifying as European-Americans were 
sampled to form a dataset containing only unrelated cases and CNEs (CCun). To account 
for population substructure of these families in association analyses, the values of the top 
two principal component loadings for each unrelated case and control were assigned to 
all members of their pedigrees to be included as covariates in the association analyses. 
For the MIRAGE cohort, a sample composed of one randomly-selected individual from 
each pedigree regardless of affection status was assembled to fit the principal component 
analysis using the EIGENSTRAT package. Outliers with respect to the cluster of 
European-Americans were excluded. The eigenvalue calculated for the sampled member 
from each pedigree was assigned to the remaining members of that pedigree. The values 
of the top three principal components were incorporated as co variates in the association 
analyses. 
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Population substructure for each of the ADC, TGEN2, GenADA, ACT, ADNI, 
ROS/MAP, OHSU, UP, WU and Mayo Clinic cohorts was examined in a two-step use of 
EIGENSTRA T software and the analysis of at least 100,000 unlinked SNPs shared 
between the study cohort and the HapMap Phase 3 CEU, Yoruban (YRI) and Chinese 
and Japanese (CHB) founders-only reference panels, selected such that MAF > 0.02 and 
pairwise r2 < 0.20 within each window of 1500 SNPs. In the first pass, the smartpca 
script from EIGENSTRA T was applied to each cohort on a merged dataset containing 
genotypes for the cohort and the three HapMap reference populations. The range and 
standard deviation of the first two principal components among the Hap Map 3 CEU 
cohort were used to classify study subjects as Caucasian. Subjects were considered 
Caucasian if the first two principal components were within 10 standard deviations of the 
range of those observed in the HapMap 3 CEU population. Following the first run, 
individuals with inconsistent race/ethnicity between self-reported data and estimates of 
the top two principal components were dropped. The EIGENSTRA T analysis was 
repeated to test for population substructure within each genetically-homogenous ethnic 
cohort. In this analysis within ethnic groups, the top ten principal components (PCs) were 
tested for association with diagnostic status and were reviewed graphically for evident 
substructure in the absence of association. The first two or three PCs for each dataset 
were included, and additional principal components were added depending on their 
association with case status. 
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Chapter 4: Application of Shapley Value Algorithm to ADGC data 
We applied the Shapley Value algorithm to genotyped and imputed data obtained from the 
ADGC (as described in Chapter 3) to prioritize candidates to be tested for interaction. In 
order to prioritize and test the best candidates for interaction, we used a backward 
elimination strategy iteratively to prune SNPs to be tested for interaction. 
4.1 An iterative backward elimination strategy to obtain the top Shapley Value SNPs 
The Shapley Value algorithm is able to capture interactions because it prioritizes SNPs 
based on their marginal contributions to coalitions in the presence of all the other SNPs in 
the genome. However this advantage is also a disadvantage because the presence of many 
noisy attributes can reduce the signal the algorithm is trying to capture. We propose an 
iterative backward elimination strategy that successively removes SNPs having low 
Shapley values and recalculates the Shapley scores in the remaining SNPs. The biological 
rationale for such a strategy is to eliminate SNPs that do not add any value to coalitions 
that determine the phenotype. The pseudo code for the iterative Shapley Value algorithm 
is outlined below: 
let n be the total number of SNPs 
let b be the total number of SNPs for which we would like to test all 2-way interactions 
while n>=b 
estimate Shapley Values for n SNPs assuming Sufficiency Principle on n SNPs 
sort Shapley Values 
remove the smallest Shapley Value SNPs (SNPs with Shapley Values<one standard 
deviation above the mean) 
end while 
return Shapley Value estimate for the top 2000 SNPs in the last iteration 
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The motivation behind this strategy is that the Shapley value estimates of the true 
functional SNPs will improve as the noisy SNPs are removed from the dataset. From the 
earlier demonstration ofthe calculation ofthe Shapley Value (in Section 2), it can be 
inferred that such a GW AS game describes the average association of coalition of SNP 
genotypes with the disease of interest. In other words, the Shapley Value estimates the 
average worth that a SNP adds to all possible coalitions in predicting the disease. It gives 
us an estimate of importance of SNPs in interactions that determine the phenotype of 
interest. In order to narrow down the search space to unravel biologically relevant 2-way 
and possibly higher order SNP interactions, an iterative backward elimination strategy 
prunes SNPs with low Shapley Values at every stage and the recalculates the value. The 
algorithm aims to prioritize SNPs which on average interact strongly with a lot of other 
SNPs in the GW AS. The SNPs which on average interact with only a few SNPs are 
eliminated. The next iteration then recalculates the relevance index amongst the highly 
interacting SNPs to fmd the ones that interact strongly within that subset of the SNPs. The 
iterative algorithm at each stage picks the best interacting SNPs from the set of SNPs used 
at that stage. The biological rationale of such an approach stems from the fact that two or 
more genes exhibiting a biologically relevant epistasis in the etiology ofthe disease must 
also interact with a lot of other genes in the pathway, which when perturbed causes the 
disease. 
To summarize, given a G WAS dataset, the algorithm calculates Shapley Values for all the 
SNPs. Based on the distribution of values, a subset of SNPs are excluded for the next 
stage. In the end, the algorithm stops at a computationally feasible number of SNPs or 
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when the distribution of Shapley Values is very tight and it is very hard to distinguish the 
highly interacting SNPs from the others. 
4.2 Strategy to analyze the ADGC datasets 
We applied the Shapley Value algorithm to the ADGC datasets to prioritize SNPs to be 
tested for interaction. The ADGC dataset comprises 15 genome-wide association studies 
in AD; 13 of which were designed as case-control studies and 2 are family-based studies 
(Table 3.2.a). In order to maximize the signal, each case-control dataset was treated as an 
independent discovery dataset and the Shapley Values were calculated within each study. 
We devised a 4-stage strategy summarized in Figure 4.2.a to find significant interactions 
in AD. The Shapley Value algorithm is applied in step 1 independently on the different 
datasets as a filter to pick SNPs that potentially contribute most to coalitions in predicting 
AD. Step 1 is followed by application of traditional regression models to test 2-way 
interactions between those SNPs. The strategy is outlined below: 
Stage 1: In stage 1 of the analysis strategy the search space for testing 2-way interactions 
was reduced to the top 2000 Shapley Value SNPs by applying the iterative backward 
elimination algorithm to each dataset independently. Testing all two way interactions 
between the top 2000 Shapley Value SNPs would lead to 1,999,000 independent tests if 
we ignore the LD between SNPs and assume each SNP-pair to be an independent test. 
Using a Bonferroni correction, interactions should attain a p-value at <2.5e-8 to attain 
statistical significance which approximately is equivalent to the genome-wide 
significance threshold in GWA studies. 
Stage 2: In Stage 2, association with AD of all2-way interactions between the top 2000 
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SNPs was tested independently in each dataset using an additive genetic coding in a 
logistic regression framework. Genotyped SNPs were coded as 0, 1, or 2 according to the 
number of minor alleles under the additive genetic model. For imputed SNPs, a 
quantitative estimate between 0 and 2 for the dose of the minor allele were used to 
incorporate the uncertainty of the imputation estimates. For each SNP pair, the regression 
model included the terms for SNP main effects, the interaction term and covariates for 
age, sex and principal components to adjust for population substructure (equation 4.2). 
Interaction between genotyped and imputed SNPs were tested for association with AD in 
each dataset separately using a logistic generalized linear model (GLM) in case-control 
datasets and a logistic generalized estimating equation (GEE) [113] in family-based 
datasets, controlling for intra-study population substructure. All analyses were performed 
using the R statistical software package [113-115]. 
AD - SNP1 + SNPZ + SNP1 x SNPZ + Age + Sex+ PC1 * + PCZ 
+ PCZ + other significant PCs 
Equation 4.2 
*Principal Components that explain population substructure associated with the phenotype 
Stage 3: Stage 3 of the analysis attempts to confirm SNP-pair interactions in stage 2 that 
were nominally significant for the interaction term at a P-value<0.05. Every interaction 
pair that was nominally significant in the any of the discovery datasets was tested in the 
other 14 GWAS datasets using the same regression model specified in equation 4.2. The 
interaction term beta estimates obtained from individual datasets were combined in a 
meta-analysis using the inverse variance method implemented in the software package 
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METAL[116] (http://www.sph.umich.edu/csg/abecasis/Metallindex.html). An additive 
model was assumed and the association results across datasets were combined by 
summing the regression coefficients weighted by the inverse variance of the coefficients. 
The meta-analysis P-value of the association was estimated by the summarized test 
statistic. Effect sizes were weighted by their inverse variance and a combined estimate 
was calculated by summing the weighted estimates and dividing by the summed weights. 
This method is robust especially for poorly imputed SNPs with low certainty, since the 
low imputation quality ensures a large variance, whereas directly genotyped or well-
imputed SNPs and datasets with large sample size maintained their effects on the fmal 
meta-analysis results because of small variances. 
Heterogeneity among odds ratios was assessed using Cochran' s Q, which was calculated 
as the weighted sum of squared differences between individual study effects and the 
pooled effect across studies, with the weights being those used in the pooling method. Q 
is distributed as a I with k (number of studies) minus 1 degrees of freedom. The P 
statistic [ 117, 118] describes the percentage of variation across studies that is due to 
heterogeneity rather than chance and is calculated as follows: P = 100% x (Q-df)/Q. 
Unlike Q it does not inherently depend upon the number of studies considered. 
Stage 4: This phase of the analysis attempts to confirm the robustness of the association 
signal amongst the significant interactions obtained in Stage 3. We determined that the 
muFor every SNP pair that has a significant interaction term at p-value<Se-6 
(approximately 3 orders of magnitude higher than the a-threshold, Table 4.3 .a) and are 
within 1 OOkB of a gene, we test the interactions of the neighboring SNPs. If both SNPs in 
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a significant SNP-pair are located in a gene, we test the 2-way interactions of every SNP 
pair in the two genes. If either SNP is outside but proximal to a gene, interactions are 
tested with 1 000 SNPs flanking either side of SNP that makes up the significant 
interaction pair. Every unique SNP interaction in accounted for in the multiple-testing 
correction taking inter-SNP LD into account (explained further in section 4.3). The 
schematic of the analysis strategy is presented in figure 4.2.a. 
4.3 Multiple Testing Correction 
We corrected for testing multiple SNP-SNP interactions after accounting for correlation 
between SNP genotypes due to linkage disequilibrium (LD). We used a method described 
by Li and Ji [ 119] that estimates the effective number (Meff) of independent tests from the 
eigenvalues ofthe correlation matrix of SNP genotypes. When running all two-way 
interactions among the top 2000 Shapley Value SNPs per dataset, the Li and Ji method 
estimates the independent effective tests using the following steps: 
1.) Run the Li and Ji algorithm for the 2000 Shapley Value SNPs to estimate Nind, the 
number of independent SNPs adjusting for LD. 
2.) The effective number of independent 2-way interactions Meffis (Equation 4.3.1) 
(Nind- 1) 
Meff = Nind X 2 
3.) Adjust the test criteria as though there were Meff independent tests using Sidak (1967) 
approximation below (Equation 4.3.2) 
1 
ap = 1- (1- ae)Meff 
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To adjust the a level for SNP interactions between two genes or two genomic regions, 
estimate separately the number of independent tests per gene or region and then calculate 
a using steps 2 and 3. 
As an illustration Table 4.3.a shows the adjustment for the top 2000 Shapley SNPs for 
every dataset and estimates the total number of independent tests for a meta-analysis and 
the significance level to correct for multiple testing. 
4.4 Running Shapley Value Algorithm on Genotyped and Imputed SNP sets in 
ADGC GW AS datasets 
The Shapley Value algorithm was applied to genotyped and imputed sets of the ADGC 
data independently. To fmd SNP-pair interactions associated with AD, the top Shapley 
Value SNPs obtained per dataset were tested for interactions using the strategy illustrated 
in Figure 4.2. The 15 ADGC studies were genotyped on a variety of platforms (Table 
3.2.b) rendering very little overlap between SNP sets. Imputing to the Hapmap2 reference 
set created a common denominator of SNPs across the studies. Applying the Shapley 
Value algorithm separately on the genotyped and imputed set of SNPs allowed us to 
evaluate the performance in the absence and presence of overlap between the datasets. The 
observations and results from the two runs are described below. 
4.4.1 Application of Shapley Value algorithm on Genotyped SNPs 
The Shapley Value algorithm was applied to the genotyped SNPs across the 13 ADGC 
case-control datasets. The two family-based studies- MIRAGE and NIA-LOAD were not 
used in the discovery stage of the analysis because the presence of related subjects might 
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overstate the contribution of some high Shapley Value SNPs and bias the results. Thus, we 
only included the 13 case-control datasets in the discovery phase of the analysis. 
Stage 1: Running the Shapley Value Algorithm on genotyped SNPs 
We calculated the Shapley values using the iterative backward elimination algorithm. At 
every iteration Shapley Values were calculated assuming the Sufficiency Principle for the 
set of SNPs for that iteration and SNPs with Shapley values less than one standard 
deviation above the mean were eliminated for the next iteration. Stringent quality control 
protocol (described in section 3.2.2) was applied to all the datasets prior to analysis. 
Additionally, to calculate Shapley Values, we also dropped SNPs with a minor allele 
frequency (MAF) less than 5% because a) rare SNPs which are almost always 
homozygous for the major allele might conflate Shapley Values and b) low MAF SNPs 
might affect the robustness of regression analysis with an interaction term. 
The histogram distribution of Shapley Values per iteration for every dataset is shown in 
Figure 4.4.1.a. Nine out ofthe 13 datasets were reduced from genome-wide coverage 
SNPs to 2000 or fewer SNPs in 4 iterations (Table 4.4.l.a). All the datasets barring the 
GENADA study show remarkable similarity in the distribution of Shapley Values at every 
iteration. Shapley Values at the first iteration have a uniform distribution over the range of 
values. Pruning the SNPs and recalculating Shapley Values over successive iterations 
result in right tailed skewed distribution. These observations suggest that the starting list 
of genome-wide SNPs contain a lot of non-informative candidates and iterative pruning 
and recalibration assigns higher Shapley Values to highly interacting SNPs resulting in a 
right-skewed distribution. The similarity in distribution of the datasets is evidence of the 
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non-randomness ofthe Shapley Value algorithm when applied to genome-wide data. The 
Shapley Values in the GENada dataset do not follow the same trend observed in other 
datasets. One probable explanation for the deviation could be the low genotyping quality 
observed in the older Affymetrix SNP-chip used for genotyping in the GENada study. 
Table 4.4.1.b lists the percentage of SNPs carried over to the next iteration at every stage. 
As a general trend, SNPs are carried over to the next stage in decreasing proportion for all 
the datasets barring GENada. The right skewing of the distribution suggests that the highly 
interacting SNPs are differentiated from non-informative SNPs in the later iterations. 
The lists of top Shapley Values across the 13 discovery datasets were largely non-
overlapping. We observed a total of25,204 unique SNPs in the 13 lists ofthe top 2000 
Shapley SNPs. 10,811 SNPs are located in 4540 genes. The little overlap in Shapley SNPs 
can be explained by diversity of platforms on which these datasets were genotyped (Table 
3.2.b). There was good concordance across datasets for the top genes that we observed in 
multiple datasets (Table 4.4.l.b). At least 3 SNPs in the APOE region were found in the 
Shapley Value lists of all the datasets suggesting that there might be significant 
interactions associated with AD in that region. SNPs in CSMD 1 and A2BP 1 were also 
present in the top Shapley Values in all datasets. 
Stage 2 and Stage 3: Interaction Testing and Meta-analysis of the top Shapley Value 
SNPs 
In stage 2, we tested all two-way interactions between the top 2000 Shapley Value SNPs 
in each dataset using the regression model specified in Equation 4.2. The SNP pairs that 
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yielded a p-value<0.05 (nominal significance) were followed up in all the other datasets 
using the same regression model. The results for the interaction term were summed up in 
an inverse-variance meta-analysis using METAL software. The results from Stage 3 meta-
analysis are displayed in table 4.4.1.c. Our analysis identified 34 SNP-pairs that have a p-
value<Se-6. SNP pairs within the APOE region are highly significant (best p=6.8e-14), 
comfortably crossing the multiple-testing threshold of 6.05e-9 (the calculation of the 
multiple testing threshold is explained in Section 4.3 and Table 4.3.a). The Shapley Value 
Algorithm identified the APOE region to be highly interacting with other genes in 
predicting AD risk. APOE is the biggest known risk factor in Alzheimer's Disease and 
several epistatic interactions with APOE has been reported in AD [61]. This suggests that 
the Shapley Value algorithm is able to pick the candidates that are most likely to interact. 
There is high LD in the APOE region and the regression model does not fully account for 
all the APOE genotypes, making it hard to explain the presence of strong interactions in 
the region. We describe interactions in the APOE region in a separate project and focus 
here on the other novel regions found by the algorithm. Apart from the APOE region, 
none of the other SNP pairs are significant at the multiple testing threshold of 6.05e-9. 
However, four additional gene pairs; CTNNA3-ATP11A, CSMDl-PRKCQ, SMPD3-
SYNE1 and MED12L-UNC5C contain SNP pairs that show strong evidence of interaction 
(p<Se-6). In Stage 4 we tested two-way interactions between all the SNPs in these gene-
pairs to boost the association signal. 
Stage 4: Following up interactions in significant gene-pairs identified in Stage 3 
Table 4.4.l.d lists the gene-pairs that we followed up for further analysis from Stage 3. 
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We tested two-way interactions between SNPs in each ofthe five gene-pairs in all the 15 
ADGC GWAS datasets and combined the results using the inverse-variance meta-
analysis. Table 4.4.1.d also lists the multiple testing thresholds for every gene-pair 
assuming each gene-pair as an independent hypothesis and accounting for LD within a 
gene. Table 4.4.1.e lists the top hits (SNP-pairs with interaction p-values<Se-6) from the 
meta-analysis. As expected, SNPs in the APOE region provide the strongest evidence of 
interaction. There is a strong boost in signal for the association of CSMD 1-PRKCQ (best 
p=3.5e-8) and there are multiple SNP-pairs (from the same LD block) that are strongly 
associated with AD. We see additional SNP-pairs in CTNNA3-ATP11A and MED12L-
UNC5C being associated with AD. There are no additional SNP-pairs associated with AD 
for SMPD6-SYNE1 at p<Se-06. 
4.4.2 Application of Shapley Value algorithm on Imputed SNPs 
We imputed the ADGC datasets to reference haplotypes from Hapmap2, Hapmap3 and the 
1000 genomes project respectively to bridge cross-platform missingness of SNPs. We 
chose the SNP set imputed to the Hapmap2 reference to apply the Shapley Value 
algorithm because it provided the most robust imputation quality estimates. Before 
running the Shapley Value algorithm on datasets we dropped SNPs with a MAF<0.05 and 
an imputation Rsq<0.8 from the analysis. As before, we dropped the family based 
MIRAGE and NIA-LOAD studies along with the OHSU case-control dataset from the 
discovery stage of the analysis because the imputation quality for a subset of OHSU 
subjects was poor on some chromosomes. 
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Stage 1: Running the Shapley Value Algorithm on Hapmap2 imputed SNPs 
We used 12 case-control ADGC datasets (excluding OHSU, MIRAGE and NIA-LOAD 
datasets) for discovery with the Shapley Value algorithm. In order to boost signal, for each 
dataset we filtered the set of good quality imputed Hapmap2 SNPs to 1,786,444 common 
SNPs present in all the discovery datasets. This step enables the implementation of the 
Shapley Value algorithm on a common set of SNPs across the datasets. The Shapley 
Value algorithm was then implemented on each study, iteratively pruning SNPs less than 
one standard deviation above the mean, and recalculating the values in the remaining 
SNPs. The imputation software outputs a probability for each of the three genotypes AA, 
Aa and aa for every SNP in every subject. We assumed the SNP genotype to be the one 
with the highest probability assigned by the imputation software. For SNPs with high 
imputation quality, the probability of the most likely genotype is close to 1. Figure 4.4.2.a 
shows the distribution of Shapley Values per dataset per iteration. The algorithm iterated 4 
times on each dataset to prune the list of SNPs to 2000 or fewer. We observe a pattern in 
all datasets (barring GenADA and the first iteration ofUM/MSSMNU) that is strikingly 
similar to the distribution observed from the implementation of the algorithm on 
Genotyped SNPs. The first iteration calculates genome-wide Shapley Values that follow a 
uniform distribution over the range of values. In the second and successive iterations the 
distribution of Shapley Values becomes more and more right-skewed suggesting the 
emergence highly interacting SNPs with high Shapley Values. Table 4.4.2.a shows the 
percentage of SNPs carried over to the next iteration after every pruning stage of the 
algorithm. The deviation of GenADA and UMIMSSMIVU datasets from the general trend 
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can be explained by an overall lower quality of imputation. The GENADA study, as 
mentioned earlier, was genotyped on the older Affymetrix SNP chip which overall has 
lower quality of genotyping thus affecting the imputation procedure. The UM/MSSMNU 
were genotyped in batches across different SNP chips, thus posing additional challenges in 
imputation such as batch effects and selective low quality in some batches. 
The top-2000 Shapley Value lists for the 12 datasets contained 23728 unique SNPs; 
10,537 SNPs were present in 2250 unique genes. At least three SNPs from the APOE 
region were represented in the Shapley Value lists of all datasets (Table 4.4.2.b ). SNPs in 
the CSMD1 gene were observed in final lists of 10 out ofthe 12 datasets. As observed in 
the implementation of the algorithm on Genotyped run, there is almost no overlap in the 
top Shapley SNPs between the datasets. The low concordance across the datasets could be 
due to different genetic background and noise added by a large number of non-informative 
SNPs. This issue is discussed in detail in Section 4.5.2. The top Shapley Value lists 
obtained from the twelve datasets prove that the each dataset is behaving independently 
and converging to SNPs that might show a stronger interaction in one particular dataset 
over others. The presence of different APOE SNPs in the different Shapley Value lists 
indicates that the algorithm is picking SNPs that are interacting at modest intensities in the 
different datasets. We hypothesize that the multi-study ADGC dataset has enough large 
enough sample size to combine these modest interactions to find significant epistasis in 
AD. 
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Stage 2 and Stage 3: Interaction Testing and Meta-analysis of the top Shapley Value 
SNPs 
We tested all two-way interactions between the top 2000 Shapley Value SNPs in each 
dataset and repeated the nominally significant interactions (p<0.05) in the other datasets. 
The results for the interaction term were summed up across the datasets in a meta-analysis 
using the METAL software. Table 4.4.2.c lists the top results from Stage 3 of the analysis 
on imputed SNPs. 41 SNP-pairs showed evidence of association of their interaction term 
with AD at p<Se-6. The strongest signal of association was from SNP-pairs in the APOE 
region which are in high LD and could represent haplotype effects. Only one independent 
signal was from SNPs in the gene-pair IRAK6-KCTD9. Several interaction-pairs 
involving SNPs in CNTNAP2, DCC, AACS and CAMK4 genes with different parts ofthe 
genome were highly significant (best p~ 1 Oe-7). We tested all two-way interactions in 
these 4 genes with the respective areas in the genome along with the IRAK6-KCTD9 in 
stage 4 of the analysis. 
Stage 4: Following up interactions in significant gene-pairs identified in Stage 3 
Table 4.4.2.d lists the 5 genomic regions that were followed up for further analysis in 
Stage 4 and the multiple testing burden associated with testing each region-pair. We 
excluded the APOE region because it was tested in Section 4.4.1. For SNPs that were 
located in intergenic regions, the nearest gene in the genome is listed (Table 4.4.2.d). We 
tested 2-way interactions between all the SNPs within the two genes identified to have a 
significant interaction with AD in Stage 3. For intergenic SNPs, the flanking 1000 SNPs 
are tested for interactions with SNPs in the corresponding gene. The strongest association 
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signals for each gene/region pair is listed in Table 4.4.2.e. At a threshold of 5e-6, we 
observed 47 significant interaction pairs for region-2, 83 for region-3 , 5 for region-4 and 
169 pairs for region-5. The best signal for association was found between the DCC-
UNCSCL gene region at p=5.9e-08 . The analysis also showed strong signals for the other 
regions tested; CNTNAP2-RFC (best p= 1.16e-07), AACS-TSHZ3 (best p=2.64e-07) and 
CAMK4-MDD (best p=3.3e-07). There were no additional SNP-pairs in the replication 
stage observed in IRAK6-KCTD9 with interaction p-values<5e-6. The top findings are 
further discussed in Section 4.5.2. 
4.5 Discussion 
4.5.1 Non-overlapping Shapley Value SNP lists 
There were 23728 unique SNPs in the top 2000 Shapley Value SNP lists obtained from 
imputed data in the 12 ADGC datasets. There is almost no overlap between the SNP lists 
across the datasets despite applying the algorithm to an initial set of 1,786,444 SNPs 
present in all the discovery datasets. Table 4.5.1 .a shows the percentage similarity 
between SNP-sets in pairs of datasets after every iteration of pruning SNPs based on 
Shapley Values. 10 out of the 12 datasets show consistent trends at every iteration but the 
GENADA and the UM/MSSMIVU are clear outliers and show independent behavior 
from the other datasets. The overall low imputation quality of these datasets could 
explain the deviation from other datasets even though the analysis was restricted to high 
quality imputed SNPs. The algorithm was implemented on a common set of SNPs across 
all the datasets and after pruning SNPs in the first iteration only 45-50% SNPs are 
common amongst the 10 datasets. However, the rank correlation between the Shapley 
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Values of SNPs in common between the pairs of datasets is very high (0.72-0.98) (Table 
4.5.1.b). In successive iterations, the percent similarity between SNPs and the associated 
rank correlation between Shapley Values of those common SNPs drops drastically to 
almost 0 at the 4th iteration. This observation explains the lack of overlap between the 
final Shapley Value lists of SNPs. After the first iteration, the high rank correlation of 
Shapley Values between the dataset pairs implies that the ordering of Shapley Values of 
SNPs common to both the datasets is very similar. But when the Shapley Values are 
recalculated in each dataset, the presence of SNPs that are not in common between the 
datasets influences the values of common SNPs and pushes them down the list. This 
leads to lower similarity and correlation of Shapley Values between datasets in 
successive iterations. The decreasing trend in the similarity and correlation between SNPs 
sets in different datasets could be largely due to the noise introduced by different genetic 
backgrounds of subjects. The small to modest interaction effects of SNPs in the datasets 
which add up to give a strong signal poses a challenge for methods like the Shapley 
Value algorithm to sift through the noise and pick the true effects that occur in all 
datasets. Another explanation of the non-overlapping Shapley lists could be that there are 
different sets of SNPs in each dataset that are interacting and forming coalitions that 
predict the phenotype. However the strong statistical significance of SNP interactions 
across datasets observed from the results of Stage 3 and 4 analyses provides contrary 
evidence that there might be common SNPs interacting modestly in all datasets. 
Two strategies can be employed that might overcome the problem of concordance of 
datasets. One approach would be to ignore the difference in the genetic make-up and 
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disease characteristics of the subjects in different studies and treat them as one large 
study for the purpose of applying the Shapley Value algorithm and prioritizing SNPs to 
be tested for interaction. The interaction tests between the top Shapley SNPs can be then 
conducted independently in each dataset and combined in a meta-analysis as per the 
protocol used in the earlier analysis. This approach would give us Shapley Values for 
SNPs averaged out over the different studies. The drawback of this approach is the 
presence of subjects in the individual studies who have different ascertainments, different 
demographics and diverse genetic backgrounds which might drown strong signals 
coming from individual datasets. Another strategy to boost the concordance between 
datasets involves modifying the pruning condition used in the iterations of the Shapley 
Value algorithm. The algorithm starts with a common set of SNPs across datasets and 
after the first pruning the similarity is reduced to 50% with a high correlation between the 
rankings of Shapley Values. Relaxing the pruning criterion to dropping SNPs that have 
Shapley Values less than the mean or the lowest 25% of the ranked SNPs could improve 
the convergence of the algorithm to common SNPs across datasets. We evaluate the 
versions of the algorithm with different pruning criteria in the simulated datasets 
(discussed in Chapter 5). 
4.5.2 Summary oflmportant Findings 
Applying the Shapley Value algorithm on the genotyped and imputed set of SNPs 
independently and testing interactions exhaustively in the top regions, we identified six 
novel regions with the best interaction p-value<5e-7; CSMDl-PRKCQ (best p=3.5e-8), 
CTNNA3-ATP11A (best p=4.16e-7), CNTNAP2-RFC3 (best p=1.6e-7), DCC-UNC5CL 
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(best p=5.9e-8), CAMK4-MMD(3.03 e-7) and AACS-TSHZ3 (best p=2.6e-7). The 
analysis also provided evidence for strong interactions in the APOE region. There are 
ongoing efforts to study the APOE region and interaction effects of APOE isoforms on 
AD risk using the ADGC cohorts. We thus, focus our attention on the novel regions found 
by this analysis independent of APOE. The interaction p-values ofthe novel regions fall 1-
2 orders of magnitude short of the significance threshold accounting for the multiple-
testing correction ( ~5e-9). However, it is interesting to note that the SNP-pairs show 
strong interaction effects in the absence of any marginal effect in predicting AD risk. 
None of the genes in the six regions were identified in the recent large GWAS studies 
published recently [53, 54, 74, 120] as candidates that might confer significant AD risk. 
Table 4.5 .2.a shows the interaction odds ratios of the SNP-pairs discovered in Stage 3 
analysis of Genotyped and Imputed SNPs. Also listed are the odds ratios and p-values of 
those SNPs when tested individually in a single locus test in the ADGC datasets. The 
traditional method of prioritizing SNPs using main effect p-values (or test statistic) would 
not have picked these SNPs (or genes) to be tested for interaction. These SNPs were 
present in the top 2000 Shapley Values in one or more datasets but if we prioritized based 
on main effect p-values the highest rank for a SNP was observed for in CNTNAP2 (main 
effect p=7e-3, rank=26,143). We analyzed the top 2000 SNPs ranked by the SNP's main-
effect p-values and the details of that analysis are provided in Section 4.6. 
Of the novel regions discovered in this study, CTNNA3, CNTNAP2, CSMDl and 
CAMK4 have interesting functions related to pathways perturbed in Alzheimer's Disease 
and other neurological disorders. CTNNA3 has been associated with AD in multiple 
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biological and genetic studies [121-123]. CSMDl has been implicated in schizophrenia 
[124], and copy-number variants in this gene have been found in AD cases [125]. 
CNTNAP2 has been implicated in multiple neurodevelopmental disorders, including 
Gilles de la Tourette syndrome [126], schizophrenia [127], epilepsy [128], ADHD [126] 
and autism[129]. CAMK4 has regulates metabolic processes such as glycogen and lipid 
metabolism and has been associated with human longevity [130, 131]. 
4.6 Prioritizing SNP interactions in the ADGC data by SNPs main-effects - Shapley 
Value versus P-value 
Traditional approaches to detect epistasis in GWAS are based on prioritizing SNPs by 
their main effects. The hypothesis behind this strategy is that SNPs modifying disease risk 
by themselves are more likely to interact with other SNPs in the genome. In this section, 
we compiled a list of the top 2000 SNPs ranked by the significance of their meta-analysis 
p-values for single-locus association tests in the 15 ADGC datasets and tested all two-way 
interactions between them. We employed the same strategy used previously in analyzing 
interactions between the top Shapley Value SNPs- each SNP pair interaction was tested 
independently in every ADGC dataset using equation 4.2 and the interaction term beta(s) 
were combined in an inverse variance meta-analysis using METAL. This analysis 
identified two regions of strong interactions affecting AD risk (Table 4.6.a). The APOE 
region contains several SNP interactions pairs that are significantly associated with AD 
and needs to be studied in detail. This region was also identified as the strongest signal by 
the Shapley Value algorithm. No SNPs in the genome-wide significant genes from the 
ADGC datasets- BINI, CLU, PICALM, CRl, MS4A4/MS4A6E, CD2AP, CD33 and 
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EPHAl , were associated in an interaction-pair with AD (p< l Oe-5). The absence of a 
signal from these genes might not necessarily rule out the presence of interactions between 
other SNP pairs (with modest to no main effects) in these genes. 
The WWOX-SLC19A3 interaction is novel and has not been studied previously in 
Alzheimer's Disease. It is hypothesized that WWOX might play a role for in steroid 
metabolism. The encoded protein is more than 90% identical to the mouse protein, which 
is an essential mediator oftumor necrosis factor-alpha-induced apoptosis, suggesting a 
similar, important role in apoptosis for the human protein. SLC19A3 gene is a member of 
the solute-carrier family and mutations in this gene cause biotin-responsive basal ganglia 
disease (BBGD) [132]; a recessive disorder manifested in childhood that progresses to 
chronic encephalopathy, dystonia, quadriparesis, and death if untreated. 
It is interesting to note that several of the strongly interacting SNPs in the WWOX were 
identified in the Shapley lists of 6 datasets (Table 4.4.2.b ). However the Shapley Value 
algorithm did not rank SNPs in SLC 19 A3 in the top 2000 of any of the 13 ADGC 
discovery datasets and failed to identify the WWOX-SLC19A3 interaction. This 
observation emphasizes the value of combining two or more search strategies in finding 
epistatic interactions in GW AS datasets. The Shapley Value algorithm is a valuable tool 
that should be used in conjunction with filtering SNPs based on strong main effects to be 
tested for interaction in GWAS datasets. 
Chapter 5: Comparison of the Shapley Value Algorithm to existing filtering 
methods 
5.1 Chi-Square and ReliefF family of methods to filter SNPs from GW AS data 
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In this chapter we contrast the properties and performance of the Shapley Value algorithm 
with other approaches used to prioritize functional and epistatic SNPs from genome-wide 
data. Methods to prioritize candidates to be tested for interaction can be broadly classified 
into a) filtering approaches and b) wrapper methods. Filtering methods preprocess the data 
by assigning a relevance index to each variable and using that to select a subset for 
analysis. The wrapper approach iteratively selects subsets of attributes (SNPs in genetic 
association data) for classification using either a deterministic or stochastic algorithm. The 
key difference between the two approaches is that the learning algorithm plays no role in 
selecting those attributes to consider in the filter approach. Filter approaches are usually 
fast and can handle genome-wide data. Wrapper approaches are computationally costly 
but can be more powerful in predicting the case/control status. The Shapley Value 
algorithm falls in the category of filtering approaches and in this section, I explore the 
competing filtering methods used to find candidates for interactions in genetic association 
data. 
Traditionally, human geneticists and genetic epidemiologists use a chi-square test of 
independence to assess the quality of individual SNPs by assigning significance after 
correcting for testing multiple SNPs. This method is efficient for filtering and prioritizing 
SNPs to be tested for epistasis if interaction effects are coupled with strong marginal 
effects. However it ignores the dependencies or interactions between genes in the absence 
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of strong main effects. 
Kira and Rendell [133] developed an algorithm called "Relief' that can detect complex 
attribute dependencies even in the absence of marginal effects. Relief estimates the 
importance of attributes through a type of nearest neighbor algorithm that selects 
neighbors (instances) from the same class (case/control status) and from the different class 
based on the vector of values across attributes. Weights (W) or quality estimates for each 
attribute (A) are estimated based on whether the nearest neighbor (nearest hit, H) of a 
randomly selected instance (R) from the same class and the nearest neighbor from the 
other class (nearest miss, M) have the same or different values. This process of adjusting 
weights is repeated for m instances. The algorithm produces weights for each attribute 
ranging from -1 (worst) to +1 (best). The time complexity ofReliefis O(m*n*a) where m 
is the number of instances randomly sampled from a dataset with n total instances and a 
attributes. Kononenko improved upon Relief [134] with Relief-F which chooses k (usually 
set to 1 0) nearest neighbors instead of just one. The ReliefF algorithm is commonly used 
in data-mining applications and has been shown to be more robust in the presence of noisy 
attributes [134, 135] compared to Relief. Relief-F captures interactions because it selects 
neighbors using all the attributes. However, noisy attributes can reduce the signal from the 
truly interacting ones. This poses a huge challenge in Genome-Wide Association Studies 
because a large number of SNPs are noisy and are not associated with the phenotype of 
interest. There are several improvements proposed to improve the performance or ReliefF. 
Moore and White [136] implemented a 'tuned' ReliefF algorithm (TuRF) that uses an 
iteratively backward elimination strategy to remove low quality estimates and re-estimates 
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the ReliefF values for the remaining attributes. The motivation behind this algorithm is 
that the ReliefF estimates of the true functional attributes will improve as the noisy 
attributes are removed from the dataset. In their paper, Moor and White [136] show that 
TuRF has improved power over Relief-F which outperforms naive chi-square test of 
independence for selecting functional attributes in a simulated datasets representing 
various epistasis models described here [137]. Another improvement to Relief-F, a 
spatially uniform ReliefF (SURF) [138] uses higher numbers of nearest neighbors within a 
predefined distance and has been shown to greatly improve the power to detect interacting 
SNPs over ReliefF. 
The Shapley Value algorithm is similar to the naive chi -square test of independence and 
ReliefF family of methods in its goal to filter the most informative sets of SNPs that might 
interact to predict the disease status of subjects. Empirical studies have shown that TuRF 
and SURF work efficiently in picking functional SNPs in simulated datasets with ~ 1000 
SNPs. However, their accuracy does not scale up to the sizes needed for truly large 
genome-scale SNP association studies. In the next section (5.2) we compare the accuracy 
of the Shapley Value Algorithm with naive chi-square method, ReliefF, TuRF and SURF 
in detecting a published interaction in an Alzheimer's GWAS study. In section 5.3 we 
compare the performance of the methods on 2 simulated epistatic models. In section 5.4 
we discuss the results from testing SNP-SNP interactions in the ADGC datasets when the 
SNPs are prioritized by their main-effect p-values and compare it to the results obtained 
from the Shapley Value approach (Section 4.4). 
5.2 Performance of Shapley, Chi-Square, ReliefF, TuRF and SURF on an 
Alzheimer's GW AS dataset 
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Late-onset Alzheimer's disease (LOAD) has been associated with the ORB-associated 
binding protein 2 (GAB2) gene in a genome-wide association study published by Coon 
and Reiman [52] in the Translational Genomics Research Institute (TGEN) study. They found 
evidence for interaction between the APOE-£4 carriers and the SNPs in the GAB2 gene. 
GAB2 was over-expressed in pathologically vulnerable neurons; the Gab2 protein was 
detected in neurons, tangle-bearing neurons, and dystrophic neuritis; and interference with 
GAB2 gene expression increased tau phosphorylation. The TGEN dataset is available 
online for download at the TGEN website (http://www.tgen.org/). 
Reiman et al investigated the association of 312,316 SNPs separately in APOE £4 carriers 
and non-carriers. A discovery cohort and two replication cohorts were used in the study. 
Within the discovery subgroup consisting of APOE ~::4 carriers, 10 ofthe 25 SNPs 
exhibiting the greatest association with LOAD (contingency test p-value 9 x 10 -s to 1 x 
10 -7) were located in the ORB-associated binding protein 2 (GAB2) gene on chromosome 
11q14.1 (figure 5.2.a). Associations with LOAD for 6 ofthese SNPs were confirmed in 
the two replication cohorts. Combined data from all three cohorts exhibited significant 
association between LOAD and all 10 GAB2 SNPs in APOE s4 carriers. These 10 SNPs 
were not significantly associated with LOAD in the APOE s4 non-carriers. 
The GWAS dataset was pruned to SNPs genotyped with reliable quality (>98% call-rate) 
in 770 cases and 480 controls. We applied the naive chi-square, ReliefF, TuRF and SURF 
filters as implemented in the MDR software [139] on four lists of SNPs from the TGEN 
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dataset created at various levels of marginal significance-p<0.05, p<O.l, p<0.2 and p<0.3. 
We also implemented the additive coding of the Shapley Value algorithm using the 
backward elimination strategy on the genotype data for those SNPs lists. We created the 
lists of SNPs based on their marginal association with AD at various significance levels to 
test the performance of the filtering algorithms at different levels of noise added by non-
functional SNPs to the real signal emitted by the GAB2 SNPs. There were 17236 SNPs at 
p<0.05, 33467 SNPs at p<0.1, 66468 SNPs at p<0.2 and 95198 at p<0.3. 
The results from the analyses are shown in Table 5.2.a. The APOE-allele proxy SNP 
"rs4420638" (not shown in the table) was ranked number 1 by all methods in all the p-
value lists. All the methods identified the APOE gene because of its huge marginal effect 
on AD status. The Shapley Value algorithm performs remarkably well at assigning a 
higher ranking to the GAB2 SNPs compared to the other algorithms. SNP rs10793294 is 
ranked in the top 500 SNPs in each of the 4 p-value based lists. This SNP is associated 
with AD in APOE £4 carriers at a p-value of 1.7e-07. The Shapley Value algorithm 
assigns increasingly higher ranking to all the GAB2 SNPs (barring rs 12280 198) as the 
lists get shorter and the number of non-functional competing SNPs is reduced. This 
provides strong evidence of the robustness of SNP ranking by the Shapley Value 
algorithm in the presence of noisy non-functional SNPs at a genome-wide level. The 
Shapley Value algorithm ranks at least two GAB2 SNPs within the top 1000 in all the p-
value lists, which allows the identification of the APOE-GAB2 interaction at a p-
value=10e-5 (assuming 1000 independent tests). Surprisingly, ranking SNPs by the Chi-
Square values performs better than the ReliefF family of methods. The moderate main 
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effects of the GAB2 SNPs on AD status allow assignment of moderate ranking to SNPs 
based on a Chi-Square test of independence. The rankings assigned by the ReliefF, TuRF 
and SURF methods look fairly random and do not follow a particular pattern. In the 
presence of noisy genome-wide SNPs, these methods fail to identify GAB2 interaction 
with APOE. This analysis provides strong evidence of the the Shapley Value algorithm 
outperforms its peers in detecting functional SNPs from genome-wide data at varying 
degrees of noise. 
5.3 Performance of Shapley Value, Chi-Square, ReliefF and TuRF on simulated 
epistasis data 
In this section we studied the performance ofthe Shapley Value algorithm in detecting 
two different models of epistasis using simulated data. Table 5.3.a depicts 2 two-locus 
interaction models simulated in this study to compare the performance of Shapley Value 
algorithm, Chi-Square, ReliefF and TuRF. The epistatic models are simulated under high 
(Modell) and low (Model2) heritability (h2 =0.4 and 0.05). The first model is a purely 
epistatic XOR interaction, first illustrated by Li and Reich. [140] and the second model 
represents a nearly additive interaction effect. The first model represents a non-linear 
interaction, whereas the second model is linear in nature where the increasing dosage of a 
allele for a SNP increases the penetrance of the disease. The 5% level represents a worst-
case scenario for heritability, and the epistatic XOR model represents the worst-case 
scenario for gene-gene interaction models. The machine learning methods show superior 
performance for non-linear interactions whereas parametric methods perform better when 
the effect is linear. These models allow us to test the performance of the Shapley Value 
73 
algorithm for the two scenarios. For each epistatic model, 100 replicate datasets were 
created with 200, 400, 800 and 1600 samples consisting of an equal number of cases and 
controls. The minor allele frequencies were set to 0.2 for both the functional loci. 
Replicate simulations were created using the genomeSim software [141]. GenomeSIM is 
capable of simulating LD patterns, but for this analysis we produced the datasets under 
assumptions of no LD. Each replicate dataset consists of a set of 1000 SNPs containing 
the two susceptibility SNPs. For the 100 replicates of each model in Table 5.3.a, we 
recorded the number of times that the two susceptibility SNPs were detected among the 
top filtered n SNPs for each analytical method. The empirical detection power in Figures 
5.3.a and 5.3.b is defined as the fraction oftimes out ofalllOO replicate data sets for a 
given model that both of the simulated susceptibility SNPs occurred in the top n SNPs as 
ranked by the given method. We chosen to vary between 50 to 500 (in intervals of 50) 
and recorded the power of the method at each accuracy level. The ReliefF methods 
perform exceedingly well in the Modell scenario when there is high heritability and the 
interaction is a non-linear XOR. However in Model 2 when the interaction is somewhat 
additive and the double heterozygotes have higher penetrances than other genotypes, the 
additive Shapley algorithm out-performs the ReliefF methods. The Chi-Square method 
works poorly in both cases because there is modest to no single locus main effect. The 
simulation study suggests that the Shapley Value algorithm is powerful in detecting 
interactions at low heritability and linear in nature. The power of the ReliefF algorithms 
can be harnessed to uncover non-linear interactions from genome-wide data. Because the 
discriminant function in the Shapley Value algorithm codes for SNPs assuming an 
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underlying model, they are somewhat parametric in nature and thus do not work well for 
non-linear interactions. However they are efficient in detecting additive and 
dominant/recessive type interactions which are observed more commonly in the biology 
of complex diseases. That coupled with the power to uncover interacting signals from 
genome-wide data in the presence oflot of noise (as demonstrated in the last section), the 
Shapley Value algorithm can be used as a quick and efficient method to narrow down 
candidates to be tested for interaction using more sophisticated downstream techniques. 
5.4 Strengths and Limitations of the Shapley Value Algorithm 
We have demonstrated in the previous sections the advantages of a Shapley Value 
approach over other filtering methods when applied to genome-wide data. The unique 
characteristic of the Shapley Value algorithm is that it combines information from several 
collaborating SNPs and evaluates the relevance of a particular SNP based on its marginal 
collaboration to such coalitions in predicting the phenotype of interest. Such coalitions 
support the theory that complex diseases such as Alzheimer's are caused by several 
hundred independent loci, each exerting a small effect on disease risk. This method allows 
us to capture such dependencies and rank SNPs by their power to affect coalitions in 
influencing the outcome of interest. It combines information from cases and healthy 
controls in a voting scenario and allows us to use the entire dataset in evaluating relevance 
of SNPs. Because of ability to combine information from cases and controls by the 
discriminant function, the Shapley Value algorithm does not suffer from the disadvantages 
of unbalanced datasets which affect other filter and wrapper-based approaches such MDR 
[ 13 7]. The Shapley Value algorithm is also not influenced by the ordering of samples 
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which affect nearest neighbor search strategies like ReliefF. Moreover, the Shapley Value 
approach allows researchers to combine datasets seamlessly if they are fairly equivalent 
and are not biased by genetic background or other sources of noise. 
The Shapley Value algorithm like other filtering methods also suffers from a few 
limitations. Attributes that make up the best coalitions affecting a phenotype would result 
in high scores to the members of that coalition. It may happen that even iftwo players, i 
and j , are assigned the highest Shapley values, the coalition of the two players, { i, j } , has 
a low value. Such scenarios might occur when players { i, j} interact with a lot of other 
players on an average but don't directly interact with each other. In this situation the 
prediction power of the two SNPs i and j combined is low. In order to overcome these 
situations we could use a concept similar to the Shapley Value, called the Interaction 
Index that evaluates the marginal contribution of pairs of attributes to larger coalitions. 
The interaction index of a pair of attributes { i,j } can be defined as 
I(i, j) = v(S u {i, j}) - v (S u {i}) - v (S u {j}) + v(S) 
However this method would involve testing pairs of attributes and in a genome-wide 
scenario, this strategy might be computationally intractable. 
The underlying assumption in the discrimination function about the mode of inheritance 
renders the Shapley Value Algorithm somewhat parametric in nature and thus fails in 
scenarios where interactions might be non-linear (as shown in Section 5.3). Even though, 
such dependencies are rare in biology, they might occur in high dimensional GWAS data. 
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Stochastic search methods such as ReliefF work better in such scenarios because there is 
no assumption made about mode of genetic transmission. 
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Chapter 6: Conclusions and Future Explorations 
This thesis explored a novel method built on the fundamentals of co-operative game 
theory to find epistasis in Alzheimer' s Disease. The motivation behind the approach is to 
use information from collaborating attributes (SNPs) while assigning relevance and not 
limited to evaluating an attribute purely on its individual effect. We applied this method to 
the Alzheimer's Disease Genetic Consortium (ADGC) datasets to harness the power of the 
large sample size ( ~ 10,000 cases and 11,000 controls) to find gene-gene interactions that 
might modify genetic risk. This dataset was previously studied in [74] by our group and 
we found four novel genes conferring AD- MS4A4/MS4A6E, CD2AP, CD33 and 
EPHA1. These fmdings will greatly improve our understanding ofthe etiology of 
Alzheimer' s Disease. 
Chapters 2 and 3 describe the game theory algorithm and the ADGC studies along with 
the quality control protocol used to create analysis-ready datasets respectively. Chapter 4 
discusses the results from application of the Shapley Value algorithm to the ADGC 
datasets and subsequently tested interactions between top ranked SNPs. Application of the 
algorithm on genotyped and imputed sets of data uncovered 6 novel regions with the best 
interaction p-value<Se-7 per region; CSMD1-PRKCQ (best p=3.5e-8), CTNNA3-
ATP11A (best p=4.16e-7), CNTNAP2-RFC3 (best p=1.6e-7), DCC-UNCSCL (best 
p=S .9e-8), CAMK4-MMD(3 .03 e-7) and AACS-TSHZ3 (best p=2.6e-7). The algorithm 
also detected presence of very strong interactions in the APOE region. To confirm the 
validity of these findings, efforts are ongoing to study these interactions in other 
independent ADGC cohorts comprising Caucasian and African American subjects. In 
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Chapter 5 we compared the Shapley Value method to prioritize SNPs to ReliefF, TuRF & 
SURF and a simple chi-square test of independence. We demonstrated that the Shapley 
Value algorithm is more robust than the ReliefF family and chi-square methods in 
predicting a previously published interaction in Alzheimer's Disease observed in a GWAS 
of APOE £4 carriers. We also contrasted the performance ofthe Shapley Value algorithm 
with the ReliefF family of methods using simulated data. The Shapley Value detects 
interacting SNPs more efficiently when the epistasis is nearly additive. The additive 
coding in the Shapley Value algorithm favors the risk homozygotes, and thus, models of 
interactions with higher penetrances for double homozygotes will be efficiently detected. 
However, the algorithm performs poorly compared to ReliefF in detecting non linear 
epistasis. Efforts are ongoing to optimize the algorithm to improve its performance in the 
presence of noise coming from a multitude of genome-wide non-functional SNPs. In our 
experiments, it has been observed that the efficiency of the algorithm depends largely on 
the pruning strategy which iteratively removes poorly contributing SNPs to boost signal 
from the truly functional SNPs. Like other filtering methods, to some extent the 
performance of the Shapley Value algorithm is determined by the initial determination of 
the Shapley Values in the fust iteration. It is possible that the truly functional SNPs are 
assigned low relevance in the first iteration and get removed from further analysis leading 
to false positives. We are also evaluating permutation strategies to determine the 
significance of Shapley Values to improve the robustness of the algorithm. Going forward, 
filtering SNPs to be tested for interaction in GW AS using a combination of Shapley 
Value, Chi-Square and other methods such as RelifF will allow researchers to detect 
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epistatic linear and non-linear interactions in genome-wide data at minimal cost of 
multiple testing. We presented here a working example of the power of game theory in 
modeling biological interactions and detecting functional relationships between SNPs 
based on their ability to form coalitions. The algorithm found novel interactions with 
SNPs that do not have strong main effects but interact to be associated with AD. Although 
these findings need to be further validated in other independent genetic and biological 
studies, the Shapley Value algorithm detected novel interactions in the presence of weak 
main effects and a lot noise from genome-wide SNPs. 
Tables and Figures 
Table 3.1 Sample size and descriptive statistics by dataset in the ADGC cohort 
Cases 
Auto Age at Age at Ctrls Cohort Cases (N) Female onset exam APOE t2/E31E4 (N) Autopsied psied (N) (mean± (mean± (allele%) (N) (N) SD) SD) 
ACT 566 70 357 83 .90 (4.8) 84.72 (4.9) 0.05/0.69/0.26 1696 155 
ADC1 1566 1566 850 72.47 (7.1) 81.61 (7.0) 0.03/0.55/0.42 515 114 
ADC2 738 195 377 73. 19 (7.1) 80.06 (7.2) 0.03/0.57/0.39 160 0 
ADNI 268 0 113 75.30 (7.2) 77.96 (6.5) 0.03/0.55/0.42 173 0 
GenADA 669 9 380 74.59 (6.2) 80.36 (6.2) 0.04/0.58/0.38 713 0 
UMNU/M 1186 409 764 74.06 (7.8) 77.48 (6.9) 0.03/0.61 /0.36 1135 136 SSM 
MIRAGE 509 0 324 7116 (6.5) 75.97 (6.6) 0.04/0.60/0.36 753 0 
NIA- 1811 492 1176 73.57 (6.7) 82.49 (7.1) 0.02/0.51 /0.46 1575 50 LOAD 
OHSU 132 132 81 86.10 (5 .5) 90.40 (5.2) 0.07/0.70/0.23 153 153 
TGEN2 864 864 633 74.91 (7.2) 82.00 (7.6) 0.04/0.57/0.40 493 493 
ADC3 897 527 490 75.00 (8.5) 80.51 (8.9) 0.04/0.59/0.37 588 4 
MAYO 728 221 419 ND 73 .89 (4.9) 0.02/0.56/0.42 1173 216 
ROSMAP 296 29 1 208 85.59 (6.3) 89.83 (5 .7) 0.05/0.75/0.20 776 0 
UP 1271 277 802 72.91 (6.4) 77.38 (6.3) 0.03/0.63/0.34 841 2 
wu 339 0 194 ND 74.23 (8.0) 0.06/0.63/0.32 187 0 
TOTAL 11840 4776 7168 -- -- -- 10931 1321 
Controls 
Age at 
Female exam 
(N, %) (mean± 
SD) 
947 81.08 (6.0) 
305 75.00 (8 .0) 
110 75.68 (7.9) 
70 78.6 (5 .5) 
456 74.21 (7.0) 
696 74.00 (8.3) 
440 72.04 (7.2) 
947 73.99 (8.5) 
84 83 .86 (7.6) 
186 80.19 (8.7) 
37 1 75.30 (9.8) 
601 73.30 (4.4) 
559 82.03 (7.0) 
533 75.37 (6. 1) 
11 3 76.85 (8.4) 
6418 
APOE 
t2/E31E4 
(a llele%) 
0.08/0.81/0.11 
0.08/0.76/0.16 
0.09/0.75/0.16 
0.08/0.79/0.14 
0.08/0.79/0.13 
0.08/0.80/0.12 
0.06/0.72/0.23 
0.07/0.73/0.20 
0.10/0.82/0.08 
0.10/0.79/0.11 
0.08/0.78/0.14 
0.08/0.77/0.15 
0.10/0.81/0.10 
0.09/0.81 /0.10 
0.07/0.78/0.15 
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Table 3.2.a Description of public availability of discovery and replication datasets for analysis 
Cohort 
ACT 
ADC (1, 2, & 3) 
ADNI 
GenADA 
UMNU/MSSM 
MIRAGE 
NIA-LOAD 
OHSU 
TGEN2 
MAYO 
ROSMAP 
UP 
wu 
ADGC Discovery 
+ Replication 
Study Website 
(ACT) http://www.grouphealthresearch.org/capabilities/clinic/clin std.html#act 
(eMERGE) https://www.mc.vanderbilt.edu/victr/dcc/projects/acc/index.php/Main Pag 
(NACC) https://www.alz.washington.edu/ 
(NCRAD) http://ncrad.iu.edu/ 
http://adni.loni .ucla.edu/ (Online Application) 
http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study id=ohs000219. v l .p 
http://www.hihg.org/ (Contact Directly) 
http://www.bumc.bu.edu/genetics/research/alzheimers-disease/ 
http://www.niageneticsinitiative.org/ 
http://www.ohsu.edu/xd/researchlcenters-institutes/neurology/alzheimers/research/data 
tissuelbiomarkers-genetics.cfin 
http :1 /www. tgen. org/research/index. cfin ?pagei d= I 065 
http://mayoresearch.mayo.edu/mayo/research/alzheimers center/ 
https://www.radc.rush.edu/res/ext/docs/Rush ADCC Data Sharing.html 
http://www.adrc.pitt.edu/neurocore.asp (Contact Directly) 
http://www.niageneticsdata.org/ (Online Application) 
(Main Study) http://alois.med.upenn.edu/adgcl 
(Dataset Access) http://www.niageneticsdata.m·g/ 
Study Contact 
(Study E-mail) 
Eric B. Larson, MD, MPH, MACP 
(larson.e@ghc.org) 
NACC: Walter Kukull, PhD 
(naccmail@u.washington.edu) 
NCRAD: Tatiana Foroud, PhD 
(alzstudy@iupui.edu) 
Andrew J. Saykin, PsyD (asaykin@iupui.edu) 
dbGaP: JAAMHDAC@mail.nih.gov 
Margaret A Pericak-Vance, PhD 
(mpericak@med.miami.edu) 
Lindsay A Farrer, PhD 
(farrer@bu.edu) 
Richard Mayeux, MD, MSc 
(mm2@columbia.edu) 
Patricia L. Kramer 
(kramer@ohsu.edu) 
Eric Reiman, MD 
(eric reiman@tgen.org) 
Steven G. Younkin, MD, PhD 
(younkin.steven@mayo.edu) 
David Bennett, MD (dbennett@rush.edu) 
Data Sharing: Gregory Klein 
(Gregorv Klein@rush.edu) 
M. Ilyas Kamboh, PhD (kamboh@pitt.edu) 
Alison M. Goate, DPhil 
(goatea@psychiatry. wustl.edu) 
Gerard Schellenberg 
(gerardsc@mail.med.upenn.edu) 
Data Sharing: Li-San Wang 
(lswang@mail.med.penn.edu) 
00 
....... 
Table 3.2.b Genotyping platform and quality control by dataset in the ADGC cohorts 
Principal 
Genotyping Number of Number of Individuals components used to Allelic Cohort SNPs with call with completeness adjust for Concordance platform 
rate threshold tht·eshold (cases/controls) population Rate• 
substructure 
ACT Illumina 660 536,993 566/1696 1 ",2nd, 3'd 0.97 
ADC1 Illumina 660 534,380 1566/515 1 ", 2nd, 3'd 0.95 
ADC2 Illumina 660 527,149 738/160 1 ", 2nd, 3'd 0.97 
ADNI Illumina 610 548,414 268/173 1 '\ 2nd 0.97 
GSK Affymetrix 500 442,833 669/713 1 '\2nd 0.91 
Illumina 550 
Illumina 1M 
UM/VU/MSSM Illumina 1M-Duo 1,477,026 1186/1135 1 '\2nd, 3'd, 4th 0.96 
Affy 6.0 
Ilium ina 61 0-Quad 
MIRAGE Illumina 610 562,414 509/753 1 '\2nd, 3'd 0.97 Illumina 330 
OHSU Illumina 370 331,230 1811/1575 1 '\2nd 0.96 
NIALOAD Illumina 610 558,930 132/153 1 ' \ 2nd 0.97 
TGEN2 Affymetrix 1M 658,617 864/493 1 '\2nd, 3'd 0.93 
ADC3 Illumina 661,363 897/588 1 '\2nd, 3'd 0.97 OllllliExpress 
MAYO Affymetrix 6.0 309,603 728/1173 1 '\ 2nd, 3'd, 4th 0.95 
ROSMAP Illumina 1M 635,774 296/776 1 '\2nd 0.97 
UP 
Illumina Omni1- 738,049 1271/841 1 '\2nd, 3'd 0.96 quad 
wu Illumina 660 546,354 339/187 1 '\ 2nd 0.97 
Total -- -- 11840/10931 
• Allelic concordance rate for imputation was calculated using the mask option to the MACH program. Values reported are the average concordance rate among all 
genotyped SNPs on chromosome 19, which showed the worst imputation quality of all chromosomes. 
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Table 3.2.c Samples excluded through sample quality control measures by dataset in the ADGC 
Control 
Low call Gender Related Not with Unclear 
Cohort 
rate mismatch Caucasian 
Age< 60 MMSE< phenotype Duplicates ness 
26 
ACT 0 2 28 215 0 168 Ill 6 
ADC1 26 24 51 290 296 32 56 43 
ADC2 23 9 4 5 4 3 23 203 
ADNI 67 0 2 58 17 0 195 39 
GSK 0 0 17 31 150 8 2 I 
UMNU/MSSM 0 0 0 0 0 0 0 149 
MIRAGE 0 0 0 0 227 0 13 0 
OHSU 20 31 43 0 0 0 254 73 
NIALOAD 0 0 0 705 643 0 486 0 
TGEN2 79 0 1 27 0 0 I 161 
ADC3 44 31 27 391 18 I 7 101 
MAYO 41 0 25 37 0 0 0 95 
ROSMAP 13 0 0 0 0 0 515 109 
UP 103 47 74 14 8 79 5 20 
wu 0 0 0 3 22 0 20 102 
Discovery + Replication 416 144 272 1,776 1,385 291 1,688 1,102 
Final Sample 
(%Original 
Sample) 
2,262 (81.0%) 
2,081 (71.8%) 
898 (76.6%) 
441 (53 .8%) 
1,382 (86.9%) 
2,321 (94%) 
1,262 (84%) 
285 (40.4%) 
3,386 (64.9%) 
1,357 (83 .5%) 
1,485 (70.5%) 
1,901 (90.6%) 
1,072 (62.7%) 
2,112 (85.8%) 
526 (78.2%) 
22,771 (76.3%) 
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Table 4.3.a Multiple Testing Correction 
Calculating the effective a threshold for the Shapley Value algoritlun on genotyped SNPs in the ADGC dataset. Method 
described by Li and Ji is used to estimate the number of independent SNPs per dataset which aids in calculation of the number 
of independent interaction tests per dataset. The total number of independent interaction tests gives an estimate of the 
significance threshold required in cross-study meta-analysis to account accurately for the multiple tests conducted 
EFFTESTS BONFERRONI EFFECTIVE 
STUDY #SNPs EFFNUM (Nind) TESTS (M.rr) ALPHA ALPHA 
ACT 2000 1336 1999000 891780 2.50E-08 5.75E-08 
ADC1 2000 1304 1999000 849556 2.50E-08 6.04E-08 
ADC2 2000 987 1999000 486591 2.50E-08 1.05E-07 
ADC3 2000 1202 1999000 721801 2.50E-08 7.11E-08 
ADNI 2000 837 1999000 349866 2.50E-08 1.47E-07 
wu 2000 765 1999000 292230 2.50E-08 1.76E-07 
GENADA 2000 1050 1999000 550725 2.50E-08 9.31E-08 
UPENN 2000 1303 1999000 848253 2.50E-08 6.05E-08 
OHSU 2000 747 1999000 278631 2.50E-08 1.84E-07 
MAYO 2000 1383 1999000 955653 2.50E-08 5.37E-08 
UMIMSSMNU 2000 1460 1999000 1065070 2.50E-08 4.82E-08 
ROS!MAP 2000 1098 1999000 602253 2.50E-08 8.52E-08 
TGEN2 2000 1080 1999000 582660 2.50E-08 8.80E-08 
TOTAL 26000* 14552 25987000 8475069 1.92E-09 6.05E-09 
*These tests are not completely independent due to overlapping SNPs in Shapley Value Lists of 
00 
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Table 4.4.1.a Running the Shapley Value Algorithm on Genotyped SNPs 
Values indicate percentage of SNPs carried over to the next iteration per dataset. The percentage of SNPs decreases per 
iteration in all datasets (barring GENADA) suggesting that highly interacting SNPs are being assigned more importance as 
noisy SNPs are removed in each iteration 
STUDY Iteration 1 Iteration 2 Iteration 3 Iteration 4 
ACT 22.35% 19.02% 14.96% 14.67% 
ADC1 22.32% 18.73% 15.18% 14.61% 
ADC2 22.32% 15.71% 16.50% 14.84% 
ADC3 22.13% 17.12% 14.68% 12.22% 
ADNI 22.27% 15.24% 14.54% 14.27% 
wu 22.47% 16.02% 14.43% 13.91% 
GENADA 15.85% 17.37% 14.35% NA 
UPENN 22.38% 18.80% 15.18% 12.80% 
OHSU 18.78% 16.10% 16.59% NA 
MAYO 21.82% 18.13% 14.91% NA 
UM/MSSMNU 21.76% 14.74% 15.85% NA 
ROSAMP 22.38% 18.85% 14.72% 12.00% 
TGEN2 22.32% 18.50% 13.95% 8.25% 
- - - -
00 
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Table 4.4.1.b List of Genes that were represented by SNPs in the top Shapley lists of at least 7 datasets 
#Data sets Genes 
13 A2BP1, CSMD1, APOE Region 
12 CNTNAP2, FHIT, MAGI2 
11 CDH13, MACROD2, PTPRD, SORCS2, WWOX 
10 ACCN1,CNTN4 
ALK, ANKS1B, CREBS, CTNNA3, GMDS, GRIN2B, KLF12, LRP1B, NAV2, OPCML, PRKG1, SOXS, 
9 TMEM132D 
ASTN2, CNTNS, FARS2, FRMD4A, GPCS, GRIK4, GRM8, KCNIP4, KIRREL3, LARGE, LOC100128095, 
8 MAML2, MY016, NAALADL2, NELL1, NTM, PARK2, PSD3, PTPRG, PTPRT, SGCZ, SLIT3, SPOCK1, 
ADAMTSL1, ADAMTSL3, ARHGEF10, CACNA2D3, CACNB2, CAMK1D, CDH4, CDKAL1, CTNNA2, 
DLG2, DPP6, DSCAM, ERC2, EYA2, GLIS3, GRID1, HRNBP3, KIAA1217, KSR2, NFATC2, NOS1AP, 
- ]___ NPAS3,0DZ3,0DZ4,PCDH9,PRKCE,RGS6,RGS7,RYR2,SDK1,STK32B,THSD7A,TOX 
00 
0\ 
Table 4.4.1.c Results from Stage 3 meta-analysis top Shapley Value Genotyped SNPs 
Results are sorted in order of significance of the meta-analysis p-value of the interaction term across the 15 ADGC datasets. 
All the results with a p<5* 1 Oe-5 are shown in the table. The analysis identifies 24 potential regions that show strong suggestive 
evidence of interaction. Only interactions in the APOE region cross the multiple testing threshold of 5e-9 
Region SNPl SNP2 Beta SE p Direction CHRl GENEl CHR2 GENE2 
24 rs4420638 rs8106922 0.44 0.06 6.8E-14 ++++++?++++??++ 19 APOC1 19 TOMM40 
24 rs439401 rs8106922 0.28 0.04 1.3E-12 ++++++ ?+-++ ??++ 19 LOC100129500 19 TOMM40 
24 rs8106922 rs439401 -0.28 0.04 1.3E-12 ------?-+--??-- 19 TOMM40 19 LOC100129500 
10 rs929S663 rs6102209 0.21 0.04 2.1E-07 ++++++++++++-++ 6 LRRC16A 20 NA 
1S rs12311057 rs3095329 -0.23 0.04 2.7E-07 --+-+-+-------- 12 LOC100288798 6 LOC100287146 
13 rs10822869 rs36886S -0.19 0.04 4.2E-07 ------+-+------ 10 CTNNA3 13 ATP11A 
10 rs929S663 rs6065285 0.20 0.04 5.1E-07 ++-+++++++++-++ 6 LRRC16A 20 NA 
23 rs10416S31 rs694S988 0.22 0.04 S.3E-07 ++++-+ ?++++ ??++ 19 NA 7 CREBS 
s rs6781601 rs4673207 -0.20 0.04 6.2E-07 --+-+---+------ 3 NA 2 ALS2 
20 rs4638670 rs177S24S 0.2S O.OS 6.7E-07 +++-++ ?+-++++++ 18 NA 10 APBB11P 
2S rs11666027 rs2280699 -0.24 o.os 6.7E-07 -----+--------- 19 NA 12 SOAT2 
18 rs1164933S rs2296254 -0.23 0.05 8.SE-07 --------------- 16 SMPD3 6 SYNE1 
22 rs1270S38 rs1329819 0.22 0.04 1.3E-06 ++-++++++++-+++ 18 NA 20 KIF16B I 
26 rs1329819 rs1271047 -0.21 0.04 1.4E-06 --+--+-----+--- 20 KIF16B 18 NA 
19 rs1157995 rs6008305 -0.1S 0.03 l.SE-06 ----+----+----- 17 BCAS3 22 NA 
3 rs11901018 rs71S375 0.19 0.04 1.9E-06 +++-+++++-+-+++ 2 NAPS s NA 
1 rs7S40413 rs1S94659 0.22 o.os 2.1E-06 +++++++++-+-+++ 1 NA s JAKMIP2 
3 rs11901018 rs16065S4 0.19 0.04 2.1E-06 +++-+++++-+-+++ 2 NAPS s NA 
4 rs1340S571 rs11180093 -0.20 0.04 2.3E-06 --+--+--------- 2 DOCK10 12 NA 
00 
--.) 
Table 4.4.1.c Continued 
Region SNPl SNP2 Beta SE p 
12 rs10512185 rs2866993 0.15 0.03 2.70E-06 
14 rs4575188 rs7895653 0.2 0.04 2.90E-06 
19 rs1157995 rs6008297 0.14 0.03 3.00E-06 
21 rs6566587 rs2072327 -0.2 0.04 3.10E-06 
9 rs6553807 rs7120248 0.14 0.03 3.10E-06 
16 rs1527063 rs2036376 0.19 0.04 3.20E-06 
16 rs1465070 rs2036376 -0.19 0.04 3.30E-06 
16 rs2011194 rs2036376 0.2 0.04 3.60E-06 
6 rs1221003 rs7669439 -0.22 0.05 4.10E-06 
17 rs9534381 rs10824034 0.22 •. 0 4.30E-06 
6 rs1231519 rs7669439 -0.22 0.05 4.50E-06 
8 rs4241991 rs10489575 0.24 0.05 4.60E-06 
11 rs1600857 rs677986 -0.18 0.04 4.60E-06 
2 rs12126234 rs11254599 -0.26 0.06 4.70E-06 
7 rs1405036 rs10931 -0.18 0.04 4.80E-06 
Direction CHRl GENEl 
++++++-++++++++ 9 NA 
-+-+-+++++++-++ 10 NA 
+++++++++-+++++ 17 BCAS3 
----+++--+--+-- 18 NA 
++++++-++++--++ 4 GLRA3 
++++-++++++++++ 12 NA 
----+---------- 12 NA 
++++-++++++++++ 12 NA 
------+-----+-- 3 MED12L 
++-+-++--+++++- 13 C13orf18 
------+-----+-- 3 MED12L 
+++++-+-+++-+++ 4 NA 
--+-+------+--+ 8 CSMD1 
-----+-+----+-- 1 NA 
----+-----++--- 3 NA 
---
CHR2 
4 
10 
22 
17 
11 
17 
17 
17 
4 
10 
4 
1 
10 
10 
17 
GENE2 
FRAS1 
ANK3 
NA 
ALDH3A1 
NA 
RHOTl 
RHOTl 
RHOTl 
UNC5C 
PRKG1 
UNC5C 
PCNXL2 
PRKCQ 
ST8SIA6 
NPTX1 
00 
00 
Table 4.4.1.d Gene Pairs that were followed up from Stage 3 analysis of the Genotyped SNPs 
Of the 24 regions identified in Stage 3 (Table 4.4.1.c ), 7 SNP-pairs were such where both SNPs were found in genes. 
Prioritizing SNPs that are found in known genes (excluding pseudo genes or open reading frame transcripts), 5 gene-pairs were 
followed up for further analysis in the Stage 4. Multiple testing thresholds are calculated assuming each gene-pair is an 
independent hypothesis. However, to accurately correct for multiple testing, the tests made in the discovery stage (Stage 2) 
should be added. 
GENE EFFNUM EFFNUM EFFECTIVE 
PAIR CHRl GENEl #SNPs Meff CHR2 GENE2 #SNPs Meff #EFFTESTS ALPHA 
1 19 APOC1 1 1 19 TOMM40 12 4 4 0.0125 
2 10 CTNNA3 1967 75 13 ATP11A 179 28 2100 2.38E-05 
3 16 SMPD3 88 13 6 SYNE1 568 77 1001 5E-05 
4 3 MED12L 318 31 4 UNC5C 467 68 2108 2.37E-05 
5 8 CSMD1 5021 44 10 PRKCQ 131 26 1144 4.37E-05 
00 
\0 
Table 4.4.1.e Results from Stage 4 analysis of genotyped SNPs 
The top hits (p-value<6.05e-6) from testing interactions between the gene-pairs that showed strongest evidence of interaction 
in Stage 3 (Table 4.4.1.d) are listed 
GENE 
PAIR SNPl SNP2 BETA SE p Direction CHRl CHR2 GENEl GENE2 
1 rs4420638 rs8106922 -0.44 0.06 6.8E-14 ------?----??-- 19 19 APOCl TOMM40 
5 rs1600857 rs11258802 -0.29 0.05 3.5E-08 --+-----------+ 8 10 CSMDl PRKCQ 
5 rs1600857 rs12358161 -0.29 0.05 4.1E-08 --+-----------+ 8 10 CSMDl PRKCQ 
5 rs10108533 rs11258802 0.27 0.05 2.1E-07 ++-+++-+++++++- 8 10 CSMDl PRKCQ 
5 rs10108533 rs12358161 0.27 0.05 2.3E-07 ++-+++-++++++++ 8 10 CSMDl PRKCQ 
1 rs4420638 rs10119 -0.29 0.06 3.4E-07 ------+----++-- 19 19 APOCl TOMM40 
2 rs10822869 rs368865 -0.19 0.04 4.2E-07 ------+-+------ 10 13 CTNNA3 ATPllA 
5 rs1482214 rs11258802 -0.25 0.05 6.SE-07 --+--+--------- 8 10 CSMDl PRKCQ 
5 rs1482214 rs12358161 -0.25 0.05 7.7E-07 --+--+--------- 8 10 CSMDl PRKCQ 
3 rs11649335 rs2296254 -0.23 0.05 8.SE-07 --------------- 16 6 SMPD3 SYNE1 
5 rs1600857 rs944715 0.20 0.04 l.OE-06 ++-++++++++-++- 8 10 CSMDl PRKCQ 
5 rs10091628 rs944715 0.21 0.04 1.6E-06 ++-++++++++-++- 8 10 CSMDl PRKCQ 
5 rs1600857 rs4750457 -0.19 0.04 2.8E-06 --+-----+--+--+ 8 10 CSMDl PRKCQ 
5 rs1600857 rs12146312 -0.18 0.04 3.3E-06 --+-----+--+--+ 8 10 CSMDl PRKCQ 
5 rs1482214 rs4750491 -0.17 0.04 3.8E-06 --+-----------+ 8 10 CSMDl PRKCQ 
4 rs1221003 rs7669439 -0.22 0.05 4.1E-06 ------+-----+-- 3 4 MED12L UNC5C 
5 rs1482214 rs944715 0.18 0.04 4.1E-06 ++-+++++-++-++- 8 10 CSMD1 PRKCQ 
5 rs1600857 rs4750491 -0.17 0.04 4.3E-06 ---+-------+--+ 8 10 CSMDl PRKCQ 
4 rs1231519 rs7669439 0.22 0.05 4.4E-06 ++++++-+++++-++ 3 4 MED12L UNC5C 
5 rs1600857 rs677986 0.18 0.04 4.6E-06 ++-+-++++++-++- 8 10 CSMD1 PRKCQ 
L__ 
-
1.0 
0 
Table 4.4.1.e Continued 
GENE 
PAIR SNPl SNP2 BETA SE p Direction CHRl CHR2 GENEl GENE2 
4 rs2141630 rs7669439 0.22 0.05 4.60E-06 ++++++-+++++-++ 3 4 MED12L UNC5C 
5 rs1482214 rs12146312 -0.17 0.04 4.60E-06 --+-----+-----+ 8 10 CSMD1 PRKCQ 
2 rs10822869 rs7325522 -0.34 0.07 4.60E-06 ------?-------- 10 13 CTNNA3 ATP11A 
5 rs1600857 rs11258959 -0.18 0.04 4.90E-06 --+-----+--+--+ 8 10 CSMD1 PRKCQ 
5 rs1600857 rs11258960 -0.18 0.04 4.90E-06 --+-----+--+--+ 8 10 CSMD1 PRKCQ 
5 rs1600857 rs7099451 0.18 0.04 4.90E-06 ++-+++++-++-++- 8 10 CSMD1 PRKCQ 
5 rs1600857 rs4750495 0.18 0.04 5.00E-06 ++-+++++-++-++- 8 10 CSMD1 PRKCQ 
5 rs1482214 rs4750457 -0.17 0.04 5.30E-06 --+-----+-----+ 8 10 CSMD1 PRKCQ 
1.0 
...... 
Table 4.4.2.a Running the Shapley Value Algorithm on Imputed SNPs 
Values indicate percentage of SNPs carried over to the next iteration per dataset. The percentage of SNPs decreases per 
iteration in all datasets (barring GENADA and UM/MSSMNU) suggesting that highly interacting SNPs are being assigned 
more importance as noisy SNPs are removed in each iteration 
Study Iteration 1 Iteration 2 Iteration 3 Iteration 4 
ACT 22.14% 18.87% 15.81% 14.48% 
ADCl 22.21% 18.59% 15.82% 13.92% 
ADC2 22.09% 15.57% 17.11% 15.62% 
ADC3 22.15% 16.79% 15.26% 13.96% 
ADNI 22.05% 15.74% 14.42% 15.49% 
wu 22.08% 16.22% 15.13% 14.04% 
GENADA 15.62% 18.83% 14.95% 14.72% 
U PENN 22.06% 17.13% 14.94% 14.62% 
MAYO 22.12% 17.72% 14.80% 12.97% 
UM/MSSM/VU 16.80% 16.68% 16.29% 16.64% 
ROSAMP 22.12% 18.00% 15.29% 14.30% 
TGEN2 22.12% 17.53% 15.05% 14.96% 
\0 
N 
Table 4.4.2.b List of Genes that were represented by SNPs in the top Shapley lists of at least 6 datasets 
#Data sets Genes 
12 APOE Region 
10 CSMD1 
9 MAGI2 
8 PTPRD 
7 A2BP1, DPP6, SGCZ 
6 ACCN1, LOC100128095, ODZ4, OPCML, PRKG1, SOXS, WWOX 
- -- - -- - - ~ · ~ 
\0 
w 
Table 4.4.2.c Results from Stage 3 meta-analysis for top imputed Shapley Value SNPs 
Results from Stage 3 meta-analysis for top Shapley Value Imputed SNPs. Results are sorted in order of significance of meta-
analysis p-value of the interaction term across the 15 ADGC datasets. All results with p<5*10e-6 are shown in the table. The 
analysis identifies 41 SNP-pairs that show strong suggestive evidence of interaction. Only interactions in the APOE region 
cross the multiple testing threshold of 6.05e-9 (Table 4.3 .a). *Regions 2-6 (excluding the APOE region) was followed up for 
further analysis in Stage 4. 
Region* SNPl SNP2 Beta StdErr p Direction CHRl GENEl CHR2 GENE2 
1 rs4420638 rs8106922 0.44 0.06 6.8E-14 ++++++?++++??++ 19 APOC1 19 TOMM40 
2 rs13247132 rs4142811 0.21 0.04 1.8E-07 ++++++++++++-+- 7 CNTNAP2 13 NA 
3 rs7746902 rs9948297 -0.18 0.04 4.4E-07 --+-+---------+ 6 NA 18 DCC 
3 rs6458189 rs9948297 -0.19 0.04 4.8E-07 --+-+---------+ 6 NA 18 DCC 
2 rs4142811 rs1842273 0.20 0.04 5.9E-07 ++++++++++++-+- 13 NA 7 CNTNAP2 
2 rs4142811 rs13242678 -0.20 0.04 6.1E-07 ------------+-+ 13 NA 7 CNTNAP2 
4 rs277420 rs1080910 -0.17 0.03 6.3E-07 ------------+-- 19 NA 12 AACS 
2 rs4142811 rs13231991 0.20 0.04 6.4E-07 ++++++++++++-+- 13 NA 7 CNTNAP2 
2 rs4142811 rs1406288 -0.20 0.04 6.4E-07 ------------+-+ 13 NA 7 CNTNAP2 
2 rs4142811 rs13222223 cribe 0.04 6.4E-07 ++++++++++++-+- 13 NA 7 CNTNAP2 
4 rs277420 rs7133614 0.17 0.03 6.7E-07 +++++++-++++-+- 19 NA 12 AACS 
5 rs367966 rs11079179 -0.15 0.03 6.9E-07 ---------+----- 5 CAMK4 17 NA 
5 rs381495 rs11079179 0.15 0.03 7.0E-07 +++++++++-+++++ 5 CAMK4 17 NA 
5 rs383360 rs11079179 0.15 0.03 7.1E-07 +++++++++-+++++ 5 CAMK4 17 NA 
5 rs452793 rs11079179 0.15 0.03 7.1E-07 +++++++++-+++++ 5 CAMK4 17 NA 
5 rs377111 rs11079179 0.15 0.03 -- _Z.lE-07 +++++++++-+++++ 5 CAMK4 17 NA 
--
1..0 
.j>. 
Region SNPl SNP2 Beta StdErr p Direction 
5 rs306078 rs11079179 0.15 0.03 7.20E-07 +++++++++-+++++ 
4 rs277420 rs10846829 -0.17 0.03 7.30E-07 -------+----+-+ 
5 rs395326 rs11079179 0.15 0.03 8.00E-07 +++++++++-+++++ 
2 rs4142811 rs13227291 -0.2 0.04 8.30E-07 ------------+-+ 
5 rs612417 rs11079179 0.15 0.03 8.60E-07 +++++++++-+++++ 
4 rs277420 rs7136220 -0.17 0.03 8.70E-07 -------+----+-+ 
2 rs4142811 rs13234757 0.19 0.04 1.30E-06 ++++++++++++-+-
2 rs4142811 rs13246788 0.19 0.04 1.30E-06 ++++++++++++-+-
2 rs4142811 rs997223 0.19 0.04 1.40E-06 ++++++++++++-+-
7 rs9538390 rs2787480 -0.21 0.04 2.30E-06 --+-+-+--------
8 rs9947256 rs998328 -0.16 0.03 2.40E-06 ---+------+-+--
9 rs16911109 rs17540780 0.17 0.04 2.70E-06 +-+++--++++++++ 
9 rs4285487 rs17540780 -0.17 0.04 2.70E-06 -+---++--------
9 rs10108310 rs17540780 0.18 0.04 2.70E-06 +-+++--++++++++ 
9 rs12550398 rs17540780 -0.17 0.04 2.70E-06 -+---++--------
9 rs1589860 rs17540780 -0.18 0.04 3.00E-06 -+---++--------
6 rs4762088 rs17053711 0.17 0.04 3.80E-06 ++++--+++++++++ 
10 rs3118399 rs6702835 0.18 0.04 4.10E-06 +-+++--++++++++ 
10 rs3118399 rs7540065 0.18 0.04 4.10E-06 +-+++--++++++++ 
10 rs3118399 rs7314 -0.18 0.04 4.30E-06 -+---++--------
6 rs17767298 rs17053711 -0.16 0.04 4.80E-06 ----++---------
Table 4.4.2.c Continued 
CHRl GENEl 
5 CAMK4 
19 NA 
5 CAMK4 
13 NA 
5 CAMK4 
19 NA 
13 NA 
13 NA 
13 NA 
13 NA 
18 NA 
8 NA 
8 NA 
8 NA 
8 NA 
8 NA 
12 IRAK3 
1 NA 
1 NA 
1 NA 
12 IRAK3 
CHR2 
17 
12 
17 
7 
17 
12 
7 
7 
7 
17 
11 
16 
16 
16 
16 
16 
8 
1 
1 
1 
8 
GENE2 
NA 
AACS 
NA 
CNTNAP2 
NA 
AACS 
CNTNAP2 1 
CNTNAP2 
CNTNAP2 
STXBP4 
NA 
NA 
NA 
NA 
NA 
NA 
KCTD9 
NA 
PRDX6 
PRDX6 
KCTD9 
1.0 
Vo 
Table 4.4.2.d Gene Pairs that were followed up from Stage 3 analysis of the Imputed SNPs 
Of the 41 SNP-pairs identified in Stage 3 (Table 4.4.2.c), only one SNP-pair was such that both SNPs were found in genes 
(IRAK3-KCTD9). We prioritized the gene-pair SNPs and the 4 most significant regions (excluding the APOE region) for 
analysis in Stage 4. Multiple testing thresholds are calculated asswning each gene-pair is an independent hypothesis. However, 
to accurately correct for multiple testing, the tests made in the discovery stage (Stage 2) should be added. 
** APOE region was excluded because it was tested in the analysis of Genotyped SNPs. 
NEAREST NEAREST #INTERACTION BONFERRONI 
REGION GENEl CHRl GENEl #SNPS GENE2 CHR2 GENE2 #SNPS TESTS CORRECTION 
2 CNTNAP2 7 CNTNAP2 3007 NA 13 RFC3 1000 3007000 1.71E-08 
UNC5CL, 
3 NA 6 APOBEC2 1000 DCC 18 DCC 1395 1395000 3.68E-08 
4 NA 19 TSHZ3 1000 AACS 12 AACS 55 55000 9.33E-07 
5 CAMK4 5 CAMK4 299 NA 17 MMD 1000 299000 1.72E-07 
6 IRAK3 12 IRAK3 37 KCTD9 8 KCTD9 34 1258 4.08E-05 
TOTAL TESTS 4757258 1.08E-08 
1,0 
0"1 
Table 4.4.2.e Results from Stage 4 analysis of imputed SNPs 
Listed are the 5 strongest association signals for every region specified in Table 4.4.2.d. 4 out of the 5 regions followed up 
from Stage 3 meta-analysis showed a stronger association signal from the discovery stage but there was no improvement in the 
IRAK6-KCTD9. 
Region SNPl SNP2 Beta SE p Direction CHRl GENEl CHR2 GENE2 
3 rs6458189 rs6508164 0.19 0.03 5.9E-08 ++-+-++-+++++++ 6 NA 18 DCC 
3 rs7746902 rs6508164 0.19 0.03 6.1E-08 ++-+-++-+++++++ 6 NA 18 DCC 
3 rs991762 rs6508164 0.21 0.04 9.7E-08 +++++++++++++++ 6 NA 18 DCC 
2 rs2373129 rs4142811 0.22 0.04 1.2E-07 ++++++++++++-+- 7 CNTNAP2 13 NA 
2 rs13247132 rs4142811 0.21 0.04 1.8E-07 ++++++++++++-+- 7 CNTNAP2 13 NA 
4 rs277420 rs12581512 -0.18 0.03 2.6E-07 -------+----+-- 19 NA 12 AACS 
5 rs367966 rs12600890 0.15 0.03 3.0E-07 ++++++-+--+++++ 5 CAMK4 17 NA 
5 rs367966 rs11079185 0.15 0.03 3.0E-07 ++++++-+--+++++ 5 CAMK4 17 NA 
5 rs367966 rs12602628 -0.15 0.03 3.1E-07 ------+-++----- 5 CAMK4 17 NA 
5 rs383360 rs12600890 -0.15 0.03 3.1E-07 ---+-++----- 5 CAMK4 17 NA 
5 rs383360 rs11079185 -0.15 0.03 3.1E-07 ------+-++----- 5 CAMK4 17 NA 
3 rs7746902 rs9964026 -0.18 0.04 3.5E-07 --+-+---------- 6 NA 18 DCC 
3 rs991762 rs9964026 -0.20 0.04 3.5E-07 --------------- 6 NA 18 DCC 
2 rs11771144 rs4142811 0.20 0.04 5.5E-07 ++++++++++++-+- 7 CNTNAP2 13 NA 
2 rs2373031 rs4142811 0.20 0.04 5.7E-07 ++++++++++++-+- 7 CNTNAP2 13 NA 
2 rs1842273 rs4142811 0.20 0.04 5.9E-07 ++++++++++++-+- 7 CNTNAP2 13 NA 
4 rs277420 rs1080910 -0.17 0.03 6.3E-07 ------------+-- 19 NA 12 AACS 
4 rs277420 rs7133614 0.17 0.03 6.7E-07 +++++++-++++-+- 19 NA 12 AACS 
4 rs277420 rs10846829 -0.17 0.03 7.3E-07 -------+----+-+ 19 NA 12 AACS 
~--
\0 
-..) 
Table 4.4.2.e Continued 
Region SNPl SNP2 Beta SE p 
4 rs277420 rs7136220 -0.17 0.03 8.70E-07 
6 rs4762088 rs17053711 0.17 0.04 3.80E-06 
6 rs17767298 rs17053711 -0.16 0.04 ~.80E-06 
-
Direction CHRl GENEl 
-------+----+-+ 19 NA 
++++--+++++++++ 12 IRAK3 
----++--------- 12 IRAK3 
--
-~ 
CHR2 
12 
8 
8 
GENE2 
AACS 
KCTD9 
KCTD9 1 
'-0 
00 
Table 4.5.1.a Percentage similarity between the datasets after every iteration of pruning SNPs based on Shapley Values 
Table values should be read as what% of SNPs in the colwnn dataset are also present in the row dataset after the ith iteration of 
pruning 
Iteration 1 
GEN u UM/VU ROS/ 
STUDY ACT ADCl ADC2 ADC3 ADNI wu ADA PENN MAYO MSSM MAP TGEN2 
ACT 48.6% 46.9% 47.6% 45.3% 46.6% 16.8% 46.5% 47.8% 31.3% 47.9% 46.8% 
ADCl 48.7% 47.2% 49.1% 45.9% 46.6% 17.2% 46.6% 47.7% 32 .2% 48.7% 46.3% 
ADC2 46.7% 47 .0% 46.6% 44.7% 45.2% 17.5% 44.3% 46.2% 31.2% 46.9% 45.6% 
ADC3 47.6% 49.0% 46.8% 46.4% 47.1% 17.1% 44.5% 47.6% 32.5% 48.4% 47.1% 
ADNI 45.1% 45.6% 44.7% 46 .2% 44.8% 17.5% 43.8% 45.5% 30.4% 45.6% 44.6% 
wu 46.5% 46.3% 45.2% 47.0% 44.8% 17.6% 45.5% 46.7% 31.1% 46.8% 46.4% 
GENADA 10.8% 11.0% 11.3% 11.0% 11.3% 11.3% 11.3% 10.8% 12.6% 10.9% 11.3% 
U PENN 46.3% 46.2% 44.3% 44.4% 43.9% 45 .5% 17.6% 45 .7% 29.3% 46.1% 45 .0% 
MAYO 47.7% 47.5% 46.2% 47.5% 45.7% 46.8% 16.9% 45.9% 32.5% 48.3% 46.8% 
UM/VU 
MSSM 23.7% 24.4% 23.7% 24.7% 23.1% 23 .6% 14.9% 22.3% 24.6% 23.8% 23.7% 1 
ROS/ : 
MAP 47.8% 48.5% 46.9% 48.3% 45.7% 46.9% 17.0% 46.2% 48.3% 31.3% 46.8% 
TGEN 46.8% 46.1% 45.7% 47.1% 44.7% 46.5% 17.5% 45.1% 46.8% 31.3% 46.8% 
\0 
\0 
Iteration 2 
GEN U UM/VU ROS/ 
STUDY ACT ADCl ADC2 ADC3 ADNI WU ADA PENN MAYO MSSM MAP TGEN2 
ACT 29.9% 16.9% 25.6% 16.5% 21.1% 3.1% 23.9% 27.1% 0.1% 26.4% 22.9% 
ADCl 29.5% 17.1% 26.1% 16.8% 21.1% 2.9% 23.9% 25.7% 0.1% 26.5% 23.0% 
ADC2 13.9% 14.2% 13.8% 10.6% 11.6% 1.9% 12.0% 12.2% 0.0% 12.8% 13.7% 
ADC3 22.8% 23.5% 14.9% 16.6% 18.0% 2.6% 20.0% 20.9% 0.1% 21.3% 19.3% 
ADNI 13.7% 14.2% 10.7% 15.5% 14.8% 3.6% 15.1% 13.6% 0.3% 14.1% 15.1% 
wu 18.0% 18.3% 12.1% 17.4% 15.2% 3.7% 17.1% 16.9% 0.1% 16.7% 18.2% 
GENADA 2.0% 1.9% 1.5% 1.9% 2.8% 2.8% 2.2% 1.9% 4.8% 1.7% 1.8% 
U PENN 21.7% 21.9% 13.2% 20.4% 16.5% 18.0% 3.2% 19.3% 0.2% 19.5% 19.3% 
MAYO 25.4% 24.4% 13.9% 22.0% 15.3% 18.5% 2.8% 20.0% 0.1% 24.9% 22.0% 
UM/VU/ 
MSSM 0.0% 0.1% 0.0% t 0.2% 0.1% 5.0% 0.1% 0.0% 0.0% 0.1% 
ROS/MAP 25.2% 25.6% 14.8% 22.8% 16.2% 18.6% 2.6% 20.5% 25.3% 0.0% 22.3% 
TGEN 21.2% 21.6% 15.4% 20.2% . 16.8o/Cl_ 19.7% 2.7% 19.8% 21.7% . _2.2% .... 21.7% 
_. 
0 
0 
Iteration 3 
GEN u UM/VU ROS/ TGEN 
STUDY ACT ADCl ADC2 ADC3 ADNI wu ADA PENN MAYO /MSSM MAP 2 
ACT 2.5% 0.7% 1.7% 0.3% 1.0% 0.0% 1.2% 2.1% 0.0% 4.4% 2.3% 
ADCl 2.5% 1.2% 1.4% 0.4% 1.1% 0.0% 1.0% 2.4% 0.1% 3.2% 1.1% 
ADC2 0.6% 1.1% 0.1% 0.0% 0.1% 0.0% 0.0% 0.1% 0.0% 0.5% 0.2% 
ADC3 1.4% 1.2% 0.1% 1.8% 2.6% 0.0% 2.3% 4.4% 0.3% 2.4% 3.8% 
ADNI 0.3% 0.3% 0.0% 1.6% 1.8% 0.0% 0.9% 1.4% 0.5% 0.5% 1.5% 
wu 0.8% 0.9% 0.1% 2.5% 1.9% 0.0% 2.8% 2.1% 0.4% 1.3% 2.5% 
GENADA 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.4% 0.0% 0.0% 
U PENN 1.1% 0.9% 0.0% 2.3% 1.0% 2.9% 0.0% 2.1% 0.5% 1.5% 3.4% 
MAYO 1.8% 2.1% 0.1% 4.5% 1.6% 2.3% 0.0% 2.2% 0.1% 3.9% 4.4% 
UM/VU/ 
MSSM 0.0% 0.1% 0.0% 0.3% 0.5% 0.4% 1.6% 0.4% 0.1% 0.1% 0.3% 
ROS/ 
MAP 4.0% 3.0% 0.5% 2.5% 0.6% 1.5% 0.0% 1.6% 4.0% 0.1% 3.9% 
TGEN 2.0% 1.0% 0.2% 3.9% 1.8% 2.7% 0.0% 3.5% 4.4% 0.4% 3.7% 
...... 
0 
...... 
Iteration 4 
STUDY ACT ADCl ADC2 ADC3 
ACT 0.9% 0.5% 0.0% 
ADCl 0.8% 1.0% 0.1% 
ADC2 0.5% 1.0% 0.0% 
ADC3 0.0% 0.1% 0.0% 
ADNI 0.0% 0.0% 0.0% 0.0% 
wu 0.2% 0.0% 0.0% 0.1% 
GENADA 0.0% 0.0% 0.0% 0.0% 
U PENN 0.0% 0.0% 0.0% 0.1% 
MAYO 0.0% 0.0% 0.0% 0.3% 
UM/VU/ 
MSSM 0.0% 0.0% 0.0% 0.0% 
ROS/ 
MAP 0.6% 0.4% 0.0% 0.0% 
TGEN 0.0% 0.1% 0.0% 0.1% 
GEN u 
ADNI wu ADA PENN MAYO 
0.0% 0.3% 0.0% 0.0% 0.0% 
0.0% 0.0% 0.0% 0.0% 0.0% 
0.0% 0.0% 0.0% 0.0% 0.0% 
0.0% 0.1% 0.0% 0.1% 0.3% 
0.2% 0.0% 0.0% 0.0% 
0.2% 0.0% 0.1% 0.1% 
0.0% 0.0% 0.0% 0.0% 
0.0% 0.1% 0.0% 0.5% 
0.0% 0.1% 0.0% 0.5% 
0.3% 0.1% 0.1% 0.0% 0.2% 
0.1% 0.0% 0.0% 0.0% 0.4% 
0.0% 2.4% 0.0% 0.5% 0.3% 
UM/VU ROS/ 
/MSSM MAP 
0.0% 0.6% 
0.0% 0.4% 
0.0% 0.0% 
0.0% 0.0% 
0.3% 0.1% 
0.1% 0.0% 
0.1% 0.0% 
0.0% 0.0% 
0.2% 0.4% 
0.0% 
0.0% 
0.0% 0.5% 
TGEN2 
0.0% 
0.1% 
0.0% 
0.1% 
0.0% 
2.1% 
0.0% 
0.4% 
0.3% 
0.0% 
0.5% 
0 
N 
Table 4.5.1.b Rank Correlation between Shapley Values of pairs of datasets after every iteration of pruning SNPs 
Iteration 1 
GENAD u UM/VU 
STUDY ACT ADCl ADC2 ADC3 ADNI wu A PENN MAYO /MSSM ROS/ MAP 
ACT 
ADCl 0.98 
ADC2 0.97 0.97 
ADC3 0.89 0 .89 0.88 
ADNI 0.77 0.76 0.77 0.70 
wu 0.86 0 .86 0.86 0.79 0.69 
GENADA -0.17 -0.18 -0.19 -0.18 -0.15 -0.20 
U PENN 0.89 0.89 0 .89 0.83 0.71 0.79 -0.19 
MAYO 0.92 0.92 0.90 0.84 0.72 0.81 -0.17 0.84 
UM/VU/MSSM -0.08 -0.10 -0.10 -0.09 -0.08 -0.09 0.01 -0.09 -0.10 
ROS/MAP 0.95 0.95 0.94 0.87 0.75 0.84 -0.19 0.87 0.90 -0.10 
TGEN 0.91 0.91 0.90 0.84 0.72 0.81 -0.16 0.83 0.86 -0.09 0.90 
-0 
\.;.) 
Iteration 2 
STUDY ACT ADCl ADC2 ADC3 
ACT 
ADCl 0.17 
ADC2 0.06 0.04 
ADC3 0.33 0.31 0 .17 
ADNI 0.17 0.24 0.08 0.51 
wu 0.23 0 .23 0.10 0.47 
GENADA -0.43 -0.42 -0.20 -0.71 
U PENN 0.25 0 .32 0 .09 0.54 
MAYO 0.33 0.33 0.05 0.53 
UM/VU/MSSM -0.70 -0.09 -0.25 -0.83 
ROS/MAP 0.24 0.19 0.03 0 .36 
TGEN 0.25 0 .22 0.07 0.41 
-
GEN 
ADNI wu ADA 
0.49 
-0.84 -0.77 
0.41 0.43 -0.79 
0.41 0.43 -0.66 
-0.93 -0.82 -0.31 
0.28 0.30 -0.51 
0 .41 0.36 -0.71 
u 
PENN MAYO 
0.49 
s, pri- -0.90 
0.31 0.39 
0.37 0.45 
UM/VU 
/MSSM 
-0.89 
-0.81 
ROS/ 
MAP 
0.32 
....... 
0 
.j::>. 
Iteration 3 
GEN u UM/VU ROS/ 
STUDY ACT ADCl ADC2 ADC3 ADNI wu ADA PENN MAYO /MSSM MAP 
ACT 
ADCl 0.16 
ADC2 -0.33 -0.36 
ADC3 -0.05 -0.10 -0.03 
ADNI 0.11 0.44 NA 0.34 
wu 0.12 -0.51 -0.21 0.32 0.16 
GENADA NA NA NA NA NA NA 
U PENN 0.17 -0.26 0.80 0.53 0.19 0.21 NA 
MAYO 0.10 0.02 0.64 0.48 -0.04 0 .04 NA 0.30 
UM/VU/MSSM -0.50 -0.30 NA -0.37 -0.25 -0.29 -0.51 -0.06 0.83 
ROS/MAP 0.18 -0.10 0.16 0 .06 0.64 0.26 NA 0.22 0.19 0.07 
TGEN 0.23 -0.04 0.24 0.24 0.00 0.46 NA _ 0.33 0.46 -0.03 0.25 
-0 
U'l 
Iteration 4 
STUDY ACT ADCl ADC2 ADC3 
ACT 
ADCl 0.97 
ADC2 -0.49 -0.86 
ADC3 NA NA NA 
ADNI NA NA NA NA 
wu NA NA NA NA 
GENADA NA NA NA NA 
U PENN NA NA NA 1.00 
MAYO NA NA NA 0.63 
UM/VU/MSSM NA NA NA NA 
ROS/MAP -0.58 -0.35 NA NA 
TGEN NA NA NA -1.00 
GEN 
ADNI wu ADA 
0.50 
NA NA 
NA NA NA 
NA NA NA 
-0.95 1.00 NA 
1.00 NA NA 
NA -0.95 NA 
u 
PENN MAYO 
-0.13 
NA -1.00 
NA 1.00 
0.33 0.95 
UM/VU 
/MSSM 
NA 
NA 
ROS/ 
MAP 
0.97 
...... 
0 
0'1 
Table 4.5.2.a SNP pairs discovered in the Stage 3 analysis of genotyped and imputed SNPs at p<Se-6 
Odds ratio for the interaction term and p-value are calculated with the main effects of the SNPs in the model. 
* Odds ratios and P-values for the interaction term when main effects are included in the regression model 
**Odds ratios and P-values of SNPs from a single locus test in a meta-analysis across the 15 ADGC datasets 
***Rank of the SNP when sorted by significance of the single locus test (out of ~2.5 million SNPs) 
SNP 1 SNP2 
I RANK RANK 
SNPl SNP2 OR* I P* FRQ ORl** P** SNPl*** FRQ OR2* P* SNP 2*** 
rs277420 rs1080910 0.84 6.3E-07 0.70 1.01 6.5E-01 1773283 0.67 1.04 3.6E-02 116043 
rs367966 rs11079179 0.86 6.9E-07 0.57 1.04 5.9E-02 183808 0.40 0.98 2.3E-01 662389 
rs4762088 rs17053711 1.18 3.8E-06 0.30 0 .95 2.0E-02 66363 0 .29 0.96 7.2E-02 222450 
rs4142811 rs1842273 1.22 5.9E-07 0.75 1.01 5.1E-01 1417991 0 .24 1.06 7.0E-03 26143 
rs11649335 rs2296254 0.80 8.6E-07 0.20 1.03 1.6E-01 469221 0.21 0 .99 7.1E-01 1945510 
rs10822869 rs368865 0.82 4.2E-07 0.29 1.00 8.3E-01 2253973 0.26 1.00 9.9E-01 2680064 
rs1600857 rs677986 0.83 4.6E-06 0.23 1.05 2.3E-02 76811 0 .75 1.00 8.7E-01 2372707 
rs1221003 rs7669439 0.81 4.1E-06 0.22 0.94 1.6E-02 53707 0.23 1.00 8.7E-01 2360926 
rs7746902 rs9948297 0.83 4.4E-07 0.71 1.00 8.3E-01 2258905 0.28 0.97 1.4E-01 418405 
- - - - -- ----
REGION 
AACS-
TSHZ3 
CAMK4-
MMD 
IRAK3-
KCTD9 
CNTNAP2-
RFC3 
SMPD3-
SYNE1 
CTNNA3-
ATP11A 
CSMD1-
PRKCQ 
MED12L-
UNC5C 
DCC-
UNC5CL 
_. 
0 
-....) 
Table 4.6.a Results from testing interactions between the top marginal p-value SNPs in the ADGC datasets 
The table lists the top 5 interactions per region that are significant at p<l Oe-6. The analysis identifies two regions with 
significant SNP-SNP interactions that confer AD risk. The APOE region shows the strongest signal and was also discovered 
by the Shapley Value algorithm. The WWOX-SLC19A3 interaction was not identified by the Shapley Value algorithm. Note, 
there were 246 SNP pairs in the Chr 19locus and 88 SNP pairs in WWOX-SLC19A3 that were significant with a p<l0-6 (due 
to strong LD in the regions), the table only shows the top 5 interactions per region 
SNPl SNP2 BETA p Direction CHRl GENEl CHR2 GENE2 
rs10119 rs157580 0.60 2.3E-47 +++++++++++++++ 19 TOMM40 19 TOMM40 
rs6859 rs3745150 -0.47 1.2E-37 --------------- 19 PVRL2 19 PVRL2 
rs387976 rs1135062 0.55 l.OE-28 ++++++++-++++++ 19 PVRL2 19 BCAM 
rs377702 rs1135062 0.47 4.6E-28 ++++++++-++++++ 19 PVRL2 19 BCAM 
rs416041 rs1135062 -0.46 2.0E-27 --------+------ 19 PVRL2 19 BCAM 
rs434395 rs7585761 0.29 1.7E-07 ++++--?++++ ??++ 16 wwox 2 SLC19A3 
rs434395 rs7586105 0.29 1.8E-07 ++++--?++++ ??++ 16 wwox 2 SLC19A3 
rs386497 rs7559871 0.28 2.0E-07 ++++--?++++ ??++ 16 wwox 2 SLC19A3 
rs417711 rs7559871 -0.27 2.0E-07 ----++ ?----??-- 16 wwox 2 SLC19A3 
rs386497 rs7586105 -0.28 2.1E-07 ----++ ?----??-- 16 wwox 2 SLC19A3 
....... 
0 
00 
Table 5.2.a Performance of filtering algorithms on the TGEN GW A Study 
The table lists GAB2 SNPs where the authors detected a significant association in APOE £4 caniers to modify disease risk. 
Four SNP lists were created by compiling lists of SNPs significant for association with AD at p<0.05, 0.1, 0.2 and 0.3 
respectively in the TGEN dataset. The algorithms were evaluated on their ability to assign higher importance (rank) to GAB2 
SNPs in the presence of varying degree of noise coming from non-functional SNPs. All the methods ranked the APOE proxy 
SNP "rs4420638" as number 1 in all the 4 priority lists (not shown in the table). The values in the cells are ranks assigned by 
the algorithm to the corresponding SNP. A lower value corresponds to a higher rank and higher importance. The Shapley 
Value algorithm consistently ranks the GAB2 SNPs the highest across all the methods. The ranking gets better as the lists get 
shorter and noise from non-functional SNPs are reduced. 
(NA indicates that the marginal p-value of the SNP didn't meet the threshold limit of that list). 
(There were 17236 SNPs at p<0.05, 33467 SNPs at p<0.1, 66468 SNPs at p<0.2 and 95198 at p<0.3) 
P<O.OS 
SNP SHAPLEY CHSQ RELIEFF TuRF SURF SHAPLEY 
rs1007837 757 3607 4349 9757 4674 1589 
rs10793294 71 5001 1740 7266 6871 162 
rs10793302 581 8784 6164 11407 5452 1319 
rs10899467 NA NA NA NA NA 1848 
rs11602622 NA NA NA NA NA NA 
rs12280198 4710 1778 10349 17073 7009 8127 
rs1385600 679 11133 5430 9758 5432 1441 
rs2373115 530 12664 6534 3664 5554 1108 
rs2450130 768 7674 3101 5346 4565 1612 
rs2458640 4438 13329 3267 11581 8095 7713 
rs2510038 711 3474 9256 5147 1498 
~4291702 470 1451 5476 9568 5229 976 
P<O.l 
CHSQ RELIEFF TuRF SURF 
4444 13579 11786 8360 
6259 2678 7774 12398 
11505 24906 20788 9931 
28178 10470 11090 9886 
NA NA NA NA 
2164 6457 6271 13170 
15101 11185 16606 9948 
17615 22858 17675 10166 
9957 12763 10612 8203 
18766 8947 8633 14685 
9502 12951 14467 9443 
1747 16485 5594 9345 
-
-0 
\0 
P<O.OS P<O.l 
SNP SHAPLEY CHSQ REUEFF TuRF SURF SHAPLEY CHSQ REUEFF TuRF SURF 
rs4945261 753 3734 4420 10939 4604 1573 4605 15823 12616 8259 
rs579711 NA NA NA NA NA NA NA NA NA NA 
rs7115850 401 1615 6074 11521 5961 832 1957 16800 9909 10893 
rs901104 Z8~ 8995 3850 11829 4625 1646 11822 19615 18559 8306 
P<0.2 P<0.3 
SNP SHAPLEY CHSQ REUEFF TuRF SURF SHAPLEY CHSQ REUEFF TuRF SURF 
rs1007837 3041 5445 57304 34181 15103 4537 6133 71881 61682 19111 
rs10793294 302 7725 12643 1975 22165 461 8762 52303 40682 28368 
rs10793302 2527 14634 63975 62549 18291 3744 16755 90670 77472 24760 
rs10899467 3560 41153 57198 4997 17924 5313 49999 80569 53037 23313 
rs11602622 3232 34845 59589 48339 19400 4839 41718 87434 64258 25790 
rs12280198 14239 2587 21328 481 24799 2885 2874 24880 21853 34303 
rs1385600 2774 19713 54143 12364 18310 4128 22791 73685 75909 24737 
rs2373115 2082 23391 62795 59042 18732 3075 27327 86371 60020 24957 
rs2450130 3073 12509 56049 6117 14564 4586 14274 60247 20694 18223 
rs2458640 401 25144 43561 23341 27886 640 29470 85192 63791 37692 
rs2510038 2873 11904 58726 45167 17244 4290 13567 79187 60021 22920 
rs4291702 1839 2073 59893 49374 16693 2675 2297 81331 68747 21694 
rs4945261 3032 5650 60456 51305 14736 4532 6375 75442 57817 18681 
rs579711 18725 40113 5362 12970 29991 26159 48614 34057 72009 45752 
rs7115850 1567 2321 58474 44242 20273 2329 2582 72651 81363 26935 
rs901104 3146 15086 61522 54824 14988 4690 17281 77262 64259 19106 
-
-0 
Table 5.3.a Heritability Models for Simulated Epistasis Data 
Heritability = 0.4 MAF=0.2 
AA A a a a 
BB 0.486 0.96 0.538 
Bb 0.947 0.004 0.811 
bb 0.64 0.606 0.909 
~ -
- --
p=0.800 q=0.200 
MODEL 1: Nearly XOR Model 
(purely epistatic non-linear interaction) 
Heritability = 0.05 MAF=0.2 
AA A a a a 
BB 0.115 0.052 0.199 
Bb 0.132 0.081 0.183 
bb 0.159 0.189 0.128 
-
p=0.800 q=0.200 
MODEL 2: Nearly Additive Model 
...... 
...... 
...... 
Figure 4.2 Analysis Strategy 
Flow chart detailing the analysis strategy to fmd significant interactions in the ADGC 
datasets using the iterative backward elimination Shapley Value Algorithm 
Stage 1 
Stage 2 
Stage 3 
Stage 4 
• Apply the iterative backward elimination Shapley Algorithm on 12 
case-control datasets 
• Eliminate at every iteration Shapley Values less than one standard 
deviation from the mean 
• Stop when the top 2000 SNPs are left 
• Rank the SNPs in order of Sha ley Value 
•Compute all two-way interactions between the top 2000 Shapley 
Value SNPs in each dataset 
• Include SNP main effects, interaction effect and co variates for age, 
sex and population substructure variables in an additive genetic 
model 
• For each dataset, compile all SNP interaction pairs which are 
nominally significant (p-value<O.OS) for the interaction term 
• For every dataset, compute association of the nominally significant 
SNP pairs in the other 14 datasets using the same model specified in 
Stage 2 
•For every nominally significant SNP-pair, meta-analyze the beta for 
the interaction term across the 15 datasets to obtain a summary 
statistic and p-value for the full dataset 
• From stage 3, compile a list of all interactions that show suggestive 
evidence of significance (p<S * 1 Oe-6) 
• Annotate the SNPs using dbSNP (build 131) 
• Filter SNP pairs where both SNPs are within a gene. If there are 
five such pairs go to the next step. If either SNP in an interaction 
pair is not in a gene, then prioritize pairs where SNPs are within 
lOOKB of the nearest gene (skip SNPs which don't have a gene 
within 1 OOKB of it locations). 
•Test interactions between all the SNPs in the gene pair (if SNP-pair 
is annotated be inside a gene) or 1000 SNPs flanking the SNP in the 
significant pair (if that SNP is in a intergenic region) 
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Figure 4.4.2.a Shapley Value histograms for genotyped SNPs per dataset 
Plots describe the distribution of Shapley Values per iteration for every study 
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The Manhattan Plots for the p-values for association with AD in stratified analysis in 
subjects with at least one APOE £4 allele. Genome-wide significant results found for 
SNPs in the GAB2 gene 
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Figure 5.3.a Performance of the filtering algorithms on 2 models of epistasis 
Each panel represents a sample size of200, 400, 800 and 1600. The x-axis is the no of 
SNPs within which the algorithm needs to rank the SNPs. y-axis is the power of the 
algorithm which is measured as the % of replicates in which the two simulated functional 
SNPs were ranked in the top n (x-axis labels) SNPs. 
The Shapley Value algorithm performs poorly in a non-linear XOR epistasis scenario 
(heritability of0.4) where TuRF achieves almost 100% accuracy. Shapley Value 
outperforms TuRF and ReliefF in the nearly additive genetic model at low heritability 
(1 %). We believe Model is more likely to be true in a disease specific epistasis scenario 
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